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ABSTRACT 
 
TITLE: DETECTION OF EXTENDED SPECTRUM 
BETALACTAMASES (ESBL) AND METHICILLIN 
RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)IN 
CHRONIC SUPPURRATIVE OTITIS MEDIA(CSOM) IN A 
TERTIARY CARE HOSPITAL 
INTRODUCTION: 
Chronic suppurative otitis media (CSOM) is one of the most 
commoninfections of the middle ear which can lead to extra cranial 
complications and intracranial complications, especially in developing 
countriesif not diagnosed early. So, early identification and detection of the 
etiological agent and its sensitivity pattern helps to prevent the complications. 
Judicial use of antibiotics helps to prevent the emergence of ESBL and MRSA 
in CSOM.  
AIMS AND OBJECTIVES: 
1. To isolate and to identify aerobic bacteria from Chronic Suppurative 
Otitis Media (CSOM) cases. 
2. To find out the antibiotic susceptibility pattern of the bacterial isolates. 
3. To detect the Extended Spectrum Beta Lactamases (ESBLs) producers 
from Gram negative bacterial isolates. 
4. To find the prevalence of Methicillin Resistant Staphylococcus aureus 
(MRSA) among Staphylococcus aureus isolates. 
MATERIALS AND METHODS: 
Total number of cases included in the study were two hundred and twelve 
Ear discharge were collected using the sterile cotton wool swabs.Direct gram 
staining was done&pusculture and bacterial identification was done.       
Antibiotic susceptibility testing was performed by the Kirby -Bauer disc 
diffusion method on MHA (Mueller Hinton agar) according to CLSI guidelines. 
Detection of ESBL producers was done by Phenotypic Confirmation Test 
Minimum Inhibitory Concentration (MIC) of Bacterial Isolates was performed 
by agar dilution method. Detection of Metallo beta lactamase (MBL) producers 
was done by Combined disc test with Ethylene diamine tetra acetic acid 
((EDTA).AmpC was detected by AmpC disc test and Ceftazidime- Imipenem 
Antagonism test (CIAT). MRSA was detected by cefoxitin disc diffusion 
method. 
RESULTS: 
Out of 212 cases of CSOM, 157 cases (74.06%) were culture positive and 
55 (25.94%) were culture negative .Among the 157 culture positive isolates, 
Gram negative organisms constitutes 113 (65.32%) and Gram positive 
organisms constituted 60 (34.68%) of the cases. The common age group 
suffering from CSOM were in the age group between 21 to 30 years 55 
(25.94%) followed by 49(23.11%) in the age group OF 31 to 40 years. Males 
110 (51.88%) were more affected than females 102(48.11%), Observations in 
this study indicates male preponderance in cases of CSOM. 
 
Pseudomonas aeruginosa 80 (46.24%) was found to be the most 
commonly isolated bacteria among the Gram negative isolates. In our study 
Staphylococcusaureus 46 (26.59%) was the most common gram positive 
organism isolated. 
 
Pseudomonas aeruginosa77(96.25%) was sensitive to amikacin and 
76(95%) sensitive to ofloxacin. Klebsiellapneumoniae 20(80%) were sensitive 
to amikacin. All the Gram negative bacterial isolates showed 100% sensitivity 
to imipenem and piperacillin/tazobactum except Pseudomonas 
aeruginosa78(97.50%). Extended spectrum beta lactamases (ESBL) producers 
isolated from Gram negative bacteria causing CSOM was 10(30.30%). 
 
Among the Staphylococcus aureus isolated, 41 (89.13%) and 40(86.95%) 
were sensitive to amikacin   and ofloxacin respectively. Staphylococcus aureus 
isolates were 100% sensitive to vancomycin and linezolid. 9(19.56%) of 
Staphylococcus aureus isolates were Methicillin resistant Staphylococcus 
aureus (MRSA). All the 9(19.56%) of MRSA were 100% sensitive to 
vancomycin and linezolid. 
All the 10 isolated ESBLs were confirmed by combined disc test and 
Minimum Inhibitory Concentration (MIC) reduction and also were subjected to 
PCR. 
1(16.66%) was found to be MBL producers by Ceftazidime- EDTA 
method,but none of them were found to be MBL producing by imipenem–
EDTA method. 
By AmpC disk test and CIAT, 3(2.65/%) were AmpC producers. 
 
CONCLUSION: 
Among the Gram negative organisms, Pseudomonas aeruginosa 80 
(46.24%) was found to be the most commonly isolated bacteria followed by 
Klebsiellapneumoniae 25 (17.09%)in our study. Staphylococcusaureus 46 
(26.59%) was the most common gram positive organism isolated. Among the 
Staphylococcus aureus, 9 (19.56%) were found to be MRSA 
AmongEnterobacteriaceae isolates 10 were found to be ESBL producers. 
Thus, it is essential to detect Extended Spectrum 
BetaLactamases(ESBL)and Methicillin Resistant Staphylococcus aureus 
(MRSA) routinely in laboratories. Administration of antibiotics should be 
prescribed cautiously to prevent the emergence of bacterial resistance in the 
hospital and community. 
Key words: Chronic Suppurative Otitis Media, Pseudomonas, ESBL, MIC, 
MRSA 
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INTRODUCTION 
Chronic suppurative otitis media (CSOM) is one of the most 
common infections of the middle ear which can cause extra cranial 
complications and intracranial complications and includes morbidity. It is 
one of the main causes of preventable hearing loss, principally in the 
developing world
1
. CSOM is believed to develop in early childhood, often 
followed by poorly managed acute otitis media, with its potential spilling 
into adulthood which accounts for recurrent episodes of chronic 
discharging ears that can last for many years. 
 
In 1996, WHO/CIBA Foundation workshop had defined Chronic 
suppurative otitis media as a stage of disease in which there is chronic 
infection of the middle ear cleft, i.e., eustachian tube, middle ear and 
mastoid and in which a non-intact tympanic membrane (e.g., perforation or 
tympanostomy tube) and discharge (otorrhoea) are present for at least 2 
weeks or more
2
.The basic feature is the presence of a non-intact tympanic 
membrane which is common to all the cases of chronic suppurative otitis 
media
3
.Around 90% of the burden is borne by the countries in the Africa, 
South-east Asia and Western Pacific regions and some ethnic minorities 
present in the Pacific Rim. CSOM is rare in the Americas, Australia, 
Europe, and the Middle East. Amongst the South-East Asian countries,  
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prevalence of India (7.8%) is high. This is a recent estimate from a survey 
conducted in a school in Tamil Nadu and is lower than earlier estimates 
which ranged from 16% - 34%
1
. 
 
CSOM is persistent and destructive disease resulting in irreversible 
sequelae leading onto serious intra and extra cranial complication
4
. 
Conductive or acquired hearing loss is worldwide, especially in children, 
and particularly in developing countries. In both children and adults, 
CSOM infections can lead to prolonged hearing loss which in turn not only 
affects the developmental impairment of linguistic, behavioural, motor and 
social skills but also the performance at school or work place5. 
Typically, viral infection of the upper respiratory tract precedes the 
disease, but soon the conditions are favourable for the middle ear to be 
invaded by pyogenic organisms
4
. The middle ear infection can spread to 
important structures such as, facial nerve, mastoid, labyrinth, lateral sinus, 
meninges and brain which can lead to facial nerve paralysis, mastoid 
abscess, labyrintitis, lateral sinus thrombosis and meningitis
6
. 
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Pseudomonas aeruginosa is a common organism causing chronic 
suppurative otitis media. Over the past few years, various researchers have 
isolated Pseudomonas from 48-98% of patients diagnosed as CSOM.  
From chronically discharging ears, the second most common organism 
isolated is Staphylococcus aureus. Reported data estimate infection rates 
from 15-30% of culture-positive draining ears. Large variety of gram-
negative organisms causes the rest of the infections. Klebsiella (10-21%) 
and Proteus (10-15%) species are slightly more common than other gram-
negative organisms
7
. 
CSOM has been given significant attention, not only because of its 
increasing incidence and, but also chronicity due to ototoxicity with both 
topical and systemic antibiotics and bacterial resistance 
5
. 
The development of multiple resistant strains of bacteria which can 
produce both primary and postoperative infections is due to the wide 
spread use of antibiotics. Persistence of low grade infections is the result of 
the indiscriminate, haphazard and half-hearted use of antibiotics and poor 
follow-up of patients. The introduction of sophisticated synthetic 
antibiotics has led to the changes in the microbiological flora and also 
increased the significance of reappraisal of the present day flora in CSOM.  
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The in vitro antibiotic sensitivity pattern is very essential for the clinician 
to plan a general outline of treatment for a patient with a chronic discharge 
in the ear
3, 4, 6
.  
Many patients with discharging ears use antibiotics before they 
approach the hospital .This alter the bacterial flora. This may lead to 
development of resistance to bacteria to antibiotics leading to treatment 
failure and persistence of discharge in the ears. It is therefore essential to 
know the bacteria causing suppurative otitis media and sensitivity which 
enables to initiate the treatment with specific antibiotics and also to prevent 
complications
8
. 
The present study aims to find out the bacteriological profile, their 
antimicrobial susceptibility pattern and to detect Extended Spectrum Beta 
Lactamases (ESBL) production and Methicillin Resistant Staphylococcus 
aureus (MRSA) among the bacterial isolates causing Chronic Suppurative 
Otitis Media. 
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AIMS AND OBJECTIVE 
1. To isolate and to identify aerobic bacteria from Chronic Suppurative 
Otitis Media (CSOM) cases. 
2. To find out the antibiotic susceptibility pattern of the bacterial 
isolates. 
3. To detect the Extended Spectrum Beta Lactamases (ESBLs) producers 
from Gram negative bacterial isolates. 
4. To detect Metallo Beta Lactamases (MBL) producers from non-
fermenters. 
5. To detect AmpC betalactamases from Gram negative bacterial 
isolates. 
6. To find the prevalence of Methicillin Resistant Staphylococcus aureus 
(MRSA) among Staphylococcus aureus isolates. 
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REVIEW OF LITERATURE 
The history of middle ear infection was found to be present as early 
as 460 B.C, when Hippocrates (460-377 BC) noted that acute ear pain with 
continued strong fever is to be dreaded, for the patient may become 
delirious and die
8
.The discovery of cholesteatoma in a skull found in 
Norfolk, UK by McKenzie and Brothwell (1967) which were thought to be 
of Anglo-Sexon date
9
.In 1829, Curveilhier described cholesteatoma as 
'pearly tumours' which was later accepted as the general term 
'cholesteatoma'. In 1854, Cholesteatoma was described by Virchow in 
detail. Evidence of previous infections in the middle ear was obvious when 
radiological evidence in the mastoid have been the subject of inquiry in 
417 temporal bones from South Dakota Indian burials and in 15 prehistoric 
Iranian temporal bones
10,11
. 
 
EPIDEMIOLOGY OF CSOM 
Disease report burden released by the National Commission of 
Macroeconomics and Health enumerates common disease conditions in 
India. Major diseases in group of maternal ,communicable, and perinatal 
conditions includes as follows HIV/AIDS, diarrheal diseases, malaria and  
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other vector borne disease, leprosy, childhood disease, and otitis media. 
Throughout the world, the burden of illness due to CSOM comprises of 
65–330 million individuals with ear discharge, out of them, 60% suffer 
from significant hearing loss. CSOM constitutes about 28,000 deaths and 
about 2 million DALYs. The burden of illness is around 90% seen mostly 
in countries such as Africa, South-east Asia and Western Pacific regions 
and some ethnic minorities in the Pacific Rim. CSOM is infrequent in the 
Americas, Australia, Europe, and the Middle East
1
. Otitis media leads to 
loss of 0.47 million disability adjusted life years (DALYs) and causes 0.1% 
of share in the total burden of disease in India
12
. A study conducted at 
Himachal Pradesh by Amar Singh et al
13
 reported that CSOM was the 
common diagnosis among the ear diseases in rural India which constitutes 
about 32.75%. In the study conducted by Kiran Gaur et al
12
, the prevalence 
of CSOM was 19.2%.Amongst the countries in South-East Asia, Thailand 
has prevalence rates which ranged from 0.9 to 4.7% whereas the 
prevalence in India was found to be high(7.8%) which was a recent 
estimate from a survey conducted in a school in Tamil Nadu and is lower 
than earlier estimates which ranged from 16% - 34%.According to Rupa et 
al, the overall prevalence rate of CSOM among Rural South Indian 
children was found to be 6%
1
.  
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RISK FACTORS OF CSOM 
Risk factors for the chronic suppurative otitis media includes 
crowded conditions, high rate of cross infection leading onto prolonged 
carriage of nasopharyngeal pathogens, early nasopharyngeal acquisition of 
otological pathogens, malnutrition and age at first episode of acute otitis 
media
2
. 
The rate of CSOM is higher among people with poverty, illiteracy, 
ignorance, poor hygiene and malnutrition, poor housing, lack of breast 
feeding, impaired immunologic status, passive smoking, frequent URI and 
lack of medical facilities
14
. 
             The susceptibility of certain races, such as the Australian 
Aborigines, Alaskan Eskimos, Greenlanders and South-western American 
Indians to CSOM is also well documented. These are the risk factors which 
possibly favour the development of CSOM by diminishing the 
immunological defenses, raising the inoculum, and encouraging earlier 
infection
1
. 
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PATHOPHYSIOLOGY OF CSOM 
CSOM commences with an acute infection. The pathophysiology of 
this disease initiates with irritation and succeeding inflammation of the 
middle ear mucosa.  Mucosal edema occurs in response to inflammation. 
Persistent inflammation finally leads to ulceration of mucosa and 
subsequent epithelial lining breakdown. The host's attempt at bringing 
down the infection or inflammation establishes as granulation tissue. This 
can produce polyps inside the middle ear cleft. The sequence of the above 
changes may continue, which in turn destroys the surrounding bony 
margins and finally leading to the several complications of CSOM15. 
 
PATHOGENESIS OF CSOM 
Perforation of tympanic membrane occurs usually secondary to acute 
otitis media. Many investigation reports that healing of tympanic 
membrane is facilitated by hyperplasia, proliferation and migration of the 
outer keratinizing squamous epithelium, the absence of which is attributed 
primarily to persistent infection
2
. The histopathological changes in CSOM 
vary with the degree and extent of the disease. The middle ear cleft is lined 
by a single layer of cuboidal or columnar epithelium. The hypotympanum  
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and the region below the horizontal course of the facial nerve contains 
goblet cells whereas the region above and behind, the lining cells are flat 
and devoid of glandular structures. 
The following changes are seen in COM without cholesteatoma: 
development of chronic inflammatory infiltrate which consists of 
lymphocytes, plasma cells and histiocytes and it is associated with 
increased capillary permeability of lamina propria of the middle ear 
mucosa and mucosal edema. The middle ear epithelium undergoes 
transformation resembling respiratory epithelium which consists of 
increased number of goblet cells and ciliated cells. The epithelium becomes 
glandular. This change also takes place in the mastoid air cells and in the 
middle ear cavity. The secretion from newly formed gland is an important 
part of the discharge seen in CSOM. Decrease in the vascularity and 
fibrosis are the characteristic feature of the late stage of the disease. These 
changes are particularly seen in mastoid air cells in which sclerosis and 
new bone formation occurs. Tympanosclerosis is a special form of fibrosis 
often seen in CSOM
16
. 
In both types of CSOM, erosion of the ossicular chain occurs. 
Erosion is due to overproduction of cytokines – interleukin -2, platelet 
derived factor, fibroblast growth factor and TNF alpha which in turn  
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promote hypervascularisation, resorption of osteoclast and bone resulting 
in damage of ossicles. Middle ear infection is more harmful the nearer it is 
to the ossicular chain and also when it is present for a longer period
17
. 
Pseudomonas aeruginosa attaches itself with the help of pili to 
necrotic or diseased epithelium of the middle ear. After attachment, 
proteases, lipopolysaccharide, and other enzymes are produced by the 
organism to prevent immunological defenses. The damage produced by 
enzymes of bacteria and inflammation results in further damage, necrosis, 
and bone erosion which can lead to some of the complications of CSOM. 
Serious complications or disseminated disease rarely occur in the normal 
immunocompetent individual
15, 18
. 
 
CLASSIFICATION OF CSOM 
CSOM is principally categorized into two types: Tubotympanic otitis 
media is disease condition which affects the pars tensa. When the pars 
flaccida part of the tympanic membrane is affected, it is known as 
atticoantral type 
3, 4, 6
. 
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TYPES OF CHRONIC SUPPURATIVE OTITIS MEDIA: 
Chronic suppurative otitis media is classified as two types: 
1. Tubotympanic disease (safe type) 
2. Atticoantral disease (unsafe type) 
 
TUBOTYMPANIC DISEASE
2, 19
 
Since it does not cause much serious complications, this is also 
called as safe disease. The infection is restricted to the antero inferior part 
of the middle ear cleft and the mucosa. In this type, there is no risk of 
erosion of bones. If present, the discharge will appear through a perforation 
in the pars tensa part of the tympanic membrane. The rim of remnant ear 
drum or intact annulus surrounds the perforation (Central 
perforation).Usually, the shape of the perforation is kidney shaped due to 
the limited blood supply to the affected portion of the ear drum. 
ATTICOANTRAL DISEASE
20
 
The atticoantral type is also known as unsafe type because it is 
associated with complications. They are associated with granulation tissue 
and cholesteatoma which may be attic or postero superior. Cholesteatoma 
is characterized by accumulation of keratinizing stratified squamous  
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epithelium in the middle ear or pneumatised part of temporal bone. It may 
be present along with infection. Cholesteatoma causes bone erosion and 
necrosis which affects the important structures such as facial nerve, inner 
ear, ossicles leading to hearing loss and intracranial complications. 
 
MICROBIOLOGY OF CSOM  
In CSOM, aerobic (e.g. Pseudomonas aeruginosa, Escherichia coli, 
Staphylococcus aureus, Streptococcus pyogenes, Proteus mirabilis, 
Klebsiella species) or anaerobic (e.g. Bacteroides, Peptostreptococcus, 
Proprionibacterium) bacteria or both may be the causative agent. The 
bacteria are occasionally present in the skin of the external auditory canal, 
but they may multiply in the presence of high humidity, inflammation, 
trauma or lacerations. These bacteria may enter the middle ear through a 
chronic perforation in the membrane
2
. 
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GRAM NEGATIVE     
BACILLI 
Pseudomonas aeruginosa 
Klebsiella pneumoniae 
Proteus spp. 
Escherichia coli 
Enterobacter spp. 
Citrobacter spp. 
Acinetobacter spp 
 
GRAM POSITIVE 
COCCI 
Staphylococcus aureus 
Coagulase Negative Staphylococcus aureus 
(CONS) 
Enterococcus faecalis 
Streptococci spp 
 
ANAEROBES 
Anaerobic Gram positive cocci 
Bacteroides spp. 
Clostridium spp. 
Prevotella spp 
 
FUNGI 
Aspergillus flavus 
Aspergillus niger 
Aspergillus fumigatus 
Candida spp. 
 
 
References from Shasidhar Viswanath et al21, and WHO report 
(2004). 
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Many studies have implicated in CSOM has found that 
Pseudomonas aeruginosa is the most common bacteria isolated from 
CSOM. The toxins and enzymes produced by Pseudomonas aeruginosa 
have been particularly responsible for the deep-seated and progressive 
destruction of middle ear and mastoid structures. Pseudomonas aeruginosa 
is an opportunistic extracellular pathogen which is frequently seen in 
chronic infection. To invade the host system two mechanisms are known. 
One of them is by producing large number of extracellular products. The 
other mechanism is by production of biofilm
2
. 
 
The most commonly isolated organism from the CSOM is 
Pseudomonas aeruginosa. 48-98% of patients with chronic ear discharge 
are due to Pseudomonas sps in several studies done earlier. 
The second most common organism isolated from chronically 
draining ears is Staphylococcus aureus. According to earlier data reports, 
15-30% of culture-positive draining ears account for infection rates. 
Remaining infections is due to various gram-negative organisms. 
Compared to other gram-negative organisms, Klebsiella (10-21%) and 
Proteus (10-15%) species are more common. 
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In 5-10% of cases, infections are polymicrobial, commonly with a 
mixture of Staphylococcus aureus and Gram-negative organisms. The 
remaining spectrum of colonizing organisms responsible for this infection 
are Fungi (Aspergillus, Candida) and  anaerobes (Bacteroides, 
Peptostreptococcus, and Peptococcus)  of which anaerobes constitutes20-
50% of the isolates causing CSOM. They are tend to be associated with 
cholesteatoma. In about 25% of cases, Fungi have been isolated, but their 
contribution to pathogenesis of this disease is unclear
7
. 
 
Biofilms are complex bacterial groups that attach to the implanted 
biomaterial or mucosal surfaces and are embedded in a slim-like 
extracellular matrix containing polysaccharides, nucleic acids and proteins 
known as extracellular polymeric substances (EPS). Since they have 
efficient defense mechanisms against the host’s immune system and against 
antimicrobial substances, they are difficult to eradicate. The importance of 
biofilms in otolaryngologic infections is becoming increasingly apparent 
Pseudomonas aeruginosa is thought to occur as a biofilm in chronic 
suppurative otitis media, and in cystic fibrosis (CF) infection of the 
airway22.Lee et al23 stated that frequency of biofilms was 60% (6 of 10) in 
CSOM. According to Lampikoskiet al
24
, the frequency of biofilms was 66%  
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(19 of 29) in mastoid mucosa with CSOM. Therefore, Roland suggested that 
biofilms are the probable causative agent of CSOM, which gives the 
explaination of the observed antibiotic resistance
25
.Ercan Kaya et al found 
that the presence of biofilms was significantly higher in patients with CSOM 
(70%).the biofilm provides an almost an impervious layer to many systemic 
and topical antibiotics and may increase the resistance to antibiotics from 
20- 100 times. Mature biofilm protects pathogenic microbes from 
antimicrobial treatment by providing a physical barrier, protecting the 
bacteria from phagocytosis and immune proteins. Microbes within biofilm 
also appear to have a lowered metabolic activity, providing further 
protection from antimicrobial treatment. Bacteria are intermittently released 
from the biofilm creating chronic or recurrent local and systemic infection. 
 
BACTERIAL RESISTANCE
26
: 
Resistance of microorganisms to drugs involve many mechanisms 
which are as follows: 
1. Certain microorganisms produce enzymes which destroy active drug. 
For ex. β lactamases produced by staphylococci and gram negative 
organisms. 
2. Some of them change their permeability to the drug 
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3. Developing an altered target for the drug or altered metabolic 
pathway which bypasses the reaction inhibited by the drug. 
4. Production of an altered enzyme that can perform its metabolic 
function but is much less affected by the drug. 
 
ORIGIN OF DRUG RESISTANCE: 
Non genetic: 
Microorganisms that are not metabolically active may be 
phenotypically resistant to drugs, but their offspring are fully susceptible. 
They can also be resistant by losing the specific target for a drug for 
several generations or they can infect the sites where the antimicrobials are 
not active 
 
 
Genetic: 
Most of the drug resistant microbes evolve as a result of genetic 
change. Chromosomal resistance develops due to spontaneous mutation in 
a locus which controls susceptibility to a given antimicrobial drug. Extra 
chromosomal resistance occurs through plasmids which carry genes for 
resistance to more than one drug. 
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LABORATORY DIAGNOSIS OF CSOM: 
Laboratory diagnosis of CSOM includes routine blood investigation, 
microscopical examination of direct gram stain, culture and sensitivity of 
ear discharge, PCR to detect bacterial DNA. 
 
 
SAMPLING COLLECTION METHODS
8
: 
 
To collect the specimens in chronic suppurative otitis media for the 
purpose of culture and sensitivity, different methods have been utilised 
which include  
1. Cotton wool swabs are used. 
2.  Discharge from external auditory meatus are collected 
3.  Aspiration  of discharge with the help of needle from the middle ear 
(tympanocentesis)  
4. Suction aspiration of the discharge from the middle ear through the 
tympanic membrane perforation. 
Though tympanocentesis increase the specificity of the culture but it 
loses its value when the discharge from the middle ear reaches the external 
auditory canal following perforation of the tympanic membrane.  
The identification of causative organisms is lost when the discharge mixes 
with the preexisting flora present in the external auditory meatus. In the 
present situation in India, both in rural and urban area there is a lack of  
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health services. Therefore in majority of cases, patients reach the ENT 
departments only after the discharge has appeared in the external auditory 
canal. In such situations, the ear discharge in the external auditory canal is 
collected with the help of cotton wool swabs or by collecting the discharge 
in a test tube or container for culture and sensitivity and it has to be relied 
by the clinician. This may not be a proper indicator of the causative agents 
in all the cases. Since the middle ear aspiration suction technique, involves 
the collection of discharge directly from the middle ear space through the 
non-intact tympanic membrane it remains to be more sensitive when it is 
compared to the two methods describes above.  In middle ear suction 
aspiration method, external contamination is very little because sterilized 
apparatus is used. Atleast 48 hours before sample collection, already 
prescribed antimicrobials/topical antibiotic drops were stopped since these 
can transfer organisms from the external auditory meatus to the middle ear 
space that can change the bacteriological picture. 
 
BETA LACTAMASES 
BETA LACTAM ANTIBIOTICS 
Beta lactam antibiotics are the ones which contain β lactam ring in 
its structure. It includes Penicillins, Cephalosporin, Monobactams and 
Carbapenem
27
. 
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MECHANISM OF ACTION
28
 
All beta lactam antibiotics inhibit the bacterial cell wall synthesis. 
The bacteria produce UDP- N – acetyl muramic acid and UDP – N – acetyl 
glucosamine. The peptidoglycan synthesis residues are linked together 
forming long strands and the UDP is split off. Transpeptidases cleaves the 
terminal D alanine of the peptide chain. The cross linking is necessary for 
the strength and rigidity of the cell wall. The beta lactam antibiotics inhibit 
the transpeptidases so that cross linking does not take place. 
 
BETALACTAMASES 
This is a heterogeneous group of penicillin recognizing proteins. 
They belong to members of super family of active site serine protease. 
These enzymes inactivate β lactam antibiotics
27
. 
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CLASSIFICATION OF BETA LACTAMASES
29
 
Schemes of functional classification that were accepted by β-
lactamase researchers include: 
(i)  In 1968, Cephalosporinases and penicillinases were grouped on 
the basis of reaction to specific antibody (Sawai et al30).  
(ii) In 1973, the Richmond and Sykes scheme classified the enzymes 
into five main divisions based on the substrate profile and the gene 
coding for β-lactamase. 
(iii) In 1989, Bush scheme classified β-lactamase on the basis of 
molecular structure and the substrate inhibition. 
(iv) In 1980, Ambler was the first to propose the Molecular structure 
classifications. 
(v) More recently, Bush, Jacoby, and Medeiros devised a classification 
scheme based on the sequence of nucleotide on the genes for 
placing β-lactamases into functional groups and on the enzyme’s 
biochemical properties and molecular structure. 
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CLASSIFICATION OF BETA LACTAMASES
29 
(Classification Schemes for Bacterial Beta Lactamases) 
 
Bush-
Jacoby-
Medeiro
s group 
1989 
Bush 
group 
Richmond-
Sykes class 
Mitsuhas
hi-Inoue 
type 
Molec
ular 
class 
Preferred 
substrates 
Inhibited by: 
 
Representative enzyme 
CAb EDTA 
1 1 
Ia,Ib,Id Csasea C 
Cephalosporins 
- - 
AmpC from Gram 
negative bacteria, MIR-
1 
2a 2a 
not 
included 
Pcase V A 
Penicillin  
+ - 
Penicillinases from 
Gram Positive bacteria 
2b 2b 
III Pcase I A 
Penicillins, 
Cephalosporins + - TEM-1, TEM-2, SHV-1 
2be 2b' 
not 
included 
except K1 
in class IV 
Cxase A 
Penicillins, 
Narrow 
spectrum and 
extended 
spectrum 
Cephalosporins
, 
Monobactams. + - 
TEM-3 to TEM-26, 
SHV-2 
to SHV-6, 
Klebsiellaoxytoca 
K1 
2br 
not 
inclu
ded 
not 
included 
not 
included 
A 
Penicillins 
± - 
TEM-30 to TEM-36, 
TRC-1 
2c 2c 
II,V 
Pcase 
IV 
A 
Penicillins,Car
benicillins + - PSE-1, PSE-3, PSE-4 
2d 2d 
V 
Pcase II, 
Pcase III 
D 
Penicillins, 
Cloxacillin 
± - 
OXA-1 to OXA-11, 
PSE-2 
(OXA-10) 
2e 2e 
1c Cxase A 
Cephalosporins 
+ - 
Inducible 
cephalosporinases 
from Proteus vulgaris 
2f 
not 
inclu
ded 
not 
included 
not 
included 
A 
Penicillins, 
Cephalosporins
, 
Carbapenems 
+ - 
NMC-A from 
Enterobacter 
cloacae, Sme-1 from 
Serratia 
marcescens 
3 3 
not 
included 
not 
included 
B 
Mostβ lactams, 
including 
carbapenems 
- + 
L1 from 
Xanthomonasmaltophili
a 
CcrA from Bacteroides 
Fragilis 
4 4 
not 
included 
not 
included 
NDc 
Penicillins 
- 
Penicillinase from 
Pseudomonas 
Cepacia 
 
a Csase, cephalosporinase; PCase, penicillinase; CXase, cefuroxime-hydrolyzing 
b-lactamase. 
b CA, clavulanic acid. 
c ND, not determined. 
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DETECTION OF BETA LACTAMASES
27, 31
 
Biochemical tests are used to detect β lactamases. β lactamases 
hydrolyses benzyl pencillin to produce penicilloic acid which was 
measured. This acid production was measured by 
1. Acidometric method: change in pH of an indicator dye is measured. 
2. Iodometric method:  
3. Chromogenic cephalosporin method: 
 
Normally Nitrocefin is yellow in colour which turns red on production of 
β-lactamases. 
 
Β LACTAMASE INHIBITORS
27
 
Beta lactamases inhibitors are enzymes that are similar to β lactam 
antibiotics. They bind either reversibly or irreversibly to beta lactamase, 
thereby preventing β lactam antibiotics from destruction. They act as 
suicide bombers, utilizing all available enzymes. Clavulanic acid, 
Sulbactam and Tazobactam are some of the examples of beta lactamases 
that has gained importance in clinical medicine. 
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EXTENDED SPECTRUM BETA LACTAMASES (ESBL) 
THE OCCURRENCE OF ESBLS 
ESBLs are β-lactamases that belong to Ambler class A. They have 
the ability to produce resistance to the first-generation cephalosporin, 
second-generation cephalosporin and third-generation cephalosporin, 
penicillins and aztreonam (but not the carbapenems or cephamycins). 
These antibiotics are hydrolysed by these enzymes. β-lactamase inhibitors 
such as clavulanic acid inhibit these enzymes
32
 and placed under Bush’s 
classification 2be
33
.  
ESBL’s are first reported in Germany in 1983 followed by France in 
1985 among Klebsiella spp. ESBL occurs in every part of the world and in 
most genera of enterobacteriaceae
32
. Generally, ESBLs are β-lactamases 
which are plasmid mediated. They are present most commonly in 
Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis and other Gram 
negative bacilli
34
. There are more than 200 different ESBLs have been 
reported33. 
Before the development of first β-lactam, penicillin, the resistance to 
β-lactam antibiotics was emerged. Chromosomal mediated β-lactamase 
was found naturally in many genera of gram negative bacteria. These  
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enzymes are believed to have developed from penicillin-binding proteins 
and show some sequence homology with them. The development was 
probably due to the selective pressure exerted by Βeta-lactam-producing 
soil organisms that are present in the environment
35
.  
The first plasmid-mediated β-lactamase, TEM-1, was described in 
the early 1960s in gram-negative bacteria. The TEM-1 enzyme was first 
reported in a strain of Escherichia coli isolated from a blood culture of the 
patient named Temoniera in Greece. 
TEM-1 is plasmid and transposon mediated, hence its spread is rapid 
in other species of bacteria. Within a short period after its first isolation, 
worldwide spread of the TEM-1 β-lactamase has spread throughout the 
world. Presently, it is found in Gram negative bacteria. SHV - 1(for 
sulphydryl variable) the next common plasmid mediated β-lactamase is 
found in Escherichia coli and Klebsiella pneumoniae. In majority of K. 
pneumoniae isolates, it is chromosomal mediated whereas it is plasmid 
mediated in E. coli
35
. 
CTX-M β lactamases, one of the most important ESBLs was 
discovered in Escherichia coli strains which was isolated from patients in 
Germany in 1989. Over the past few years, Cefotaximase (CTX-M) was  
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found in several genera of Enterobacteriaceae particularly in Escherichia 
coli and Klebsiella pneumoniae.  Cefotaxime, which is a broad spectrum 
cephalosporin, is efficiently hydrolysed by the CTX-M enzymes which can 
also be inhibited by β lactamase inhibitors such as clavulanic acid, 
tazobactam and sulbactam. There are over 60 different subtypes of CTX-M 
identified. On the basis of their amino acid sequences, they have been 
grouped under five different clusters - CTX-M-I, CTX-M-II, CTX-M-III, 
CTX-M-IV, CTX-M-IV
36
. Over the past few years, CTX-M type has 
become a global problem amid the clinical isolates of the family 
Enterobacteriaceae. Hospital outbreaks of these enzymes have been 
reported in various countries of the world
37
. 
The emerging role in the acquisition of drug resistance is the gene 
transfer among bacteria and the main cause of resistance transmission is 
known to be the horizontal dissemination of resistance genes38. Irrational 
use antibiotic use is also a risk factor for acquiring an ESBL-producing 
organism. It was found that there was a strong relationship present between 
acquisition of ESBL producing strain and use of third generation 
cephalosporin
32
. Plasmids that code for ESBL enzymes may also carry co-
resistant genes for other non-beta lactam antibiotics like 
aminoglycosides
32,33
. 
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PREVALENCE OF ESBLs IN INDIA 
In India, the prevalence of ESBLs has reached epidemic proportions, 
which ranges from 62% - 100% in Klebsiella spp and Escherichia coli 
which was obtained from  infection of skin and soft tissue, blood stream 
infections and respiratory infections as seen in the 10 Indian medical centre 
SENTRY study
39
.Generally, the rate of ESBL was 84% in SENTRY 
surveillance taken in India. As part of the SARI (2004–2006) study
40
, out 
of the 163 Gram negative isolates tested the prevalence of ESBL was 88%. 
In India, a study was conducted in nine centres, each representing 
different cities in several regions of India: NewDelhi, Mumbai, Bangalore, 
Chennai, Tamil Nadu, Hyderabad, Kolkata, Lucknow and Indore, ESBL 
producing isolates were observed  in high rates which indicates that ESBL 
producers are not only found throughout  the country but to every single 
city or region. In addition to TEM and SHV ESBL types, isolates from 
India also produces CTX-M enzymes
39
.
 
Presently, ESBLs are rising as major problem for patients not only in 
hospitals but also in long-term care facilities and community. These 
bacteria have not only become endemic but have caused outbreaks in 
various hospitals all over the world32. Therefore, it is imperative to detect 
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the ESBL production in clinical microbiology laboratory to guide the 
clinicians to provide appropriate therapy
33
 
METHODS FOR DETECTION OF EXTENDED SPECTRUM BETA 
LACTAMASES 
SCREENING OF ESBL 
1. Disc Diffusion method
32,34,41
 
The disc diffusion methods are the screening test for ESBL 
production by Escherichia coli, Klebsiella and Proteus mirabilis as 
proposed by CLSI 2013.Laboratories use cefotaxime, ceftazidime, 
cefpodoxime, ceftriaxone and aztreonam for the screening of ESBL 
production. More than one of these antibiotics should be used to improve 
the sensitivity of the detection. If the screening test is positive, it should be 
confirmed by phenotypic confirmatory test. 
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CLSI Recommendations for ESBL Detection 
41
 
Drugs(cephalosporins) 
CLSI (M100-S23) recommended 
Zone diameter(sensitive) 
Cefotaxime ≥27mm 
Ceftriaxone ≥25mm 
Ceftazidime ≥22mm 
Cefpodoxime ≥17mm 
Aztreonam ≥27mm 
 
III. ESBL Detection methods recommended by Clinical Laboratory 
Standard Institute (CLSI)
41.
 
1. Phenotypic confirmatory test/ Disc Potentiation Test
32,34,41
 
The CLSI advocates the phenotypic confirmatory test for the 
detection of production of ESBL by Klebsiella and Escherichia coli which 
use the cefotaxime or ceftazidime discs (30µg) with or without clavulanate 
(10µg). Confluent growth of test organism on Mueller Hinton agar shows 
difference of 5mm along the cephalosporin with clavulanate disc compared 
to cephalosporin disc alone. 
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2. Double disc synergy test
32,34,41
 
 In Mueller – Hinton agar plate a lawn culture of the test organism is 
done on which third generation cephalosporin disc (Ceftazidime, 
Cefotaxime or Ceftriaxone) and Augmentin are placed 30 mm apart. When 
zone of inhibition of cephalosporin extends towards 
Amoxycillin/clavulanate disc, it is taken as positive for production of 
ESBL. 
 
 
3. Broth Micro dilution
32
 
Disc potentiation test can also be done using broth microdilution 
assays by using ceftazidime (0.25to128µg/ml), ceftazidime with 
clavulanate (0.25/4 to128/4 µg/ml), cefotaxime (0.25 to64µg/ml), and 
cefotaxime with clavulanate (0.25/4 to 64/4 µg/ml) decrease in MIC of two 
fold serial dilution of cephalosporin with clavulanate compared to the MIC 
of cephalosporin alone suggests positive for ESBL production. 
 
 
4. Minimum Inhibitory Concentration
42
 
Minimum inhibitory concentration was performed by agar dilution 
method. Mueller Hinton agar was prepared in glass petri plates and 
sterilized by autoclaving which is then cooled to 50 ˚c in a water bath. 
Third generation cephalosporins like cefotaxime, ceftazidime was prepared  
 39 
 
 
 
in serial dilutions in sterile distilled water .it was brought to a final 
concentration ranging from 2µg to 2048µg/ml. at 50 ˚c antibiotics were 
added to the medium and mixed well which was poured into sterile culture 
plates. The medium has to be used immediately to retain the potency. For 
each test, test medium without the antibiotic was prepared and used as 
control plate. 
 
 
Media Preparation 
Freshly prepared and autoclaved Mueller Hinton agar is allowed to 
cool in a 50˚c water bath. Preparation of serial dilution of 3
rd
 generation 
cephalosporin (ceftazidime, cefotaxime) was prepared in sterile distilled 
water which gives a final concentration of 2µg – 2048µg/ml of agar. The 
drugs are added to the medium at 50˚c. It is mixed well and poured onto 
sterile petri plates. Test medium without the antibiotic was used as control 
plate for each series of test. 
 
Preparation of Inoculum  
3-5 well isolated colonies belonging to same morphological type 
should be taken and mixed in about 4-5 ml of a suitable broth medium in a 
sterile test tube. At a temperature of 35˚c, the broth culture was kept for  
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incubation till it attains 0.5 McFarland turbidity medium. This suspension 
corresponds to150 million organisms/ml. 
 
Test plate inoculation 
0.003ml of inoculum was added to appropriate quadrants divided on 
the plates of various concentrations and incubated at a temperature of 37º c 
for a time period of 16-20 hrs. Minimum inhibitory concentration is the 
least concentration at which there is no visible growth. Various 
concentration of cephalosporin with 4 micrograms/milliliters of clavulanic 
acid ranging from 0.5µg to 2048µg/ml of agar was tested with isolates and 
the MIC was obtained. 
 
COMMERCIAL METHODS AVAILABLE TO DETECT ESBL 
(i) Epsilometer-Test for ESBLs
43,44
 
Plastic drug impregnated strips are produced by AB bio disk in 
which one end contains a gradient of ceftazidime (MIC test ranges from 
0.5µg - 32µg/ml) and with a ceftazidime gradient and constant 
concentration of clavulanate (4µg/ml). The manufacturer recommends 
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about eight – fold decrease in MIC in the combination with 
clavulanate. The sensitivity of this method is reported as 87-100% and the 
specificity as 100%. 
(ii)  Vitek ESBL
44: 
Vitek ESBL cards contain cefotaxime and ceftazidime alone and 
cephalosporin plus constant concentration of clavulanate. Cards are 
inoculated in the same manner as that for regular Vitek cards. Cards are 
analysed automatically as soon as the growth in the control well has 
attained a set threshold. A prefixed reduction in the growth of cefotaxime 
and ceftazidime plus clavulanic acid containing wells is compared with the 
growth in the wells having cefotaxime/ceftazidime alone, indicates positive 
for ESBL producer. The sensitivity and specificity of the test is more than 
90%. 
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(iii) Molecular ESBL detection techniques 
Test Advantages Disadvantages 
DNA Probes 
Specific for gene family(e.g., 
TEM or SHV) 
Labour intensive, cannot 
distinguish between ESBLs and 
non ESBLs, and between variants 
of TEM or SHV 
PCR 
Easy to perform, specific for 
gene family(e.g., TEM or 
SHV) 
cannot distinguish between 
ESBLs and non ESBLs, and 
between variants of TEM or SHV 
Oligotyping Detects specific TEM variants 
Requires specific oligonucleotide 
probes, labour intensive, cannot 
detect new variants. 
PCR- RFLP 
Easy to perform, can detect 
specific nucleotide changes  
Nucleotide changes must result in 
altered restriction site for 
detection. 
PCR- SSCP 
Can distinguish between a 
number of SHV variants 
Requires special electrophoresis 
conditions. 
 
Nucleotide 
sequencing 
Gold standard, can detect all 
variants 
Labour intensive, can be 
technically challenging, can be 
difficult to interpret manual 
methods. 
Real Time PCR 
Rapid identification, minimum 
cross contamination 
Expensive, technical skill required 
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METALLO BETA LACTAMASES 
Metallo-β-lactamases (MBL’s) are carbapenemases produced mainly 
by Pseudomonas aeruginosa which require zinc at the site of action. They 
are designated in Ambler’s Class B and Bush-Jacoby Medeiros Group 3. 
They hydrolyze virtually all β-lactam agents such as penicillin, 
cephalosporin, including the carbapenems
45
. 
Pseudomonas aeruginosa producing metallo-β-lactamases (MBLs) 
was reported first in Japan in the year 1991 and subsequently it has been 
isolated from several parts of the world, including Asia, Australia, Europe, 
North America, and South America 46. 
Till now seven major types of MBL were described worldwide – 
IMP, SPM, VIM, GIM, SIM, AIM-1 and NDM-1. Among them, blaIMP 
and blaVIM are the most common types of MBLs that are prevalent 
worldwide. From India, only blaVIM and NDM-1 have been reported in P. 
aeruginosa in the past
45
.  
VIM (Veronese Imipenemase) enzymes have been categorised into 
three main groups designated VIM-1, VIM-2, and VIM-7. Until now, 
among Pseudomonas aeruginosa isolates, VIM-2 is spread extensively,  
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whereas VIM-1 is usually restricted to Enterobacteriaceae isolates at least 
27 unique variants are present in the IMP sub lineage which differs by up 
to 22% amino acid sequence divergence (between IMP-9 and IMP-19) that 
show important difference in structure and function from each other or 
from enzymes of other sub lineages. Determinants of IMP-type MBL are 
usually found in Enterobacteriaceae, Pseudomonas aeruginosa, and 
Acinetobacter baumannii isolates, though in other organisms (e.g., 
Pseudomonas putida) they have also been identified sporadically 
45
. 
 
TESTS TO DETERMINE METALLO BETA LACTAMASES 
AMONG NON FERMENTERS
45, 46 
SCREENING FOR MBL 
An isolate of P. aeruginosa was considered screen-test positive for 
MBL when it was Imipenem resistant: 10 µg (IPM) and/or Meropenem: 
10µg (MEM) and/or Ceftazidime: 30 µg (CAZ). Antibiotic sensitivity was 
done by the Kirby-Bauer disc diffusion method as per CLSI 
recommendation. 
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CONTROLS 
P. aeruginosa (blaVIM and blaIMP positive: CMC, Vellore) and 
ATCC 27853 were used as positive and negative controls in all tests 
performed. 
 
CONFIRMATION OF MBL PRODUCTION 
All screen-test positive isolates were subjected to: 
 
DOUBLE DISC SYNERGY TEST
45
 
In this test, Imipenem (10 µg), Meropenem (10 µg), Ceftazidime (30 
µg) discs were kept on the  Mueller Hinton agar (MHA) plate  already 
seeded with test organism matching 0.5 McFarland (10
8
CFU/ml) . The 
discs are kept with centre to centre distance of 20 mm from a disc 
containing 5 µl 0.5 M EDTA (930 mg). Plates were incubated at 37°C for 
18-20 hours. Enhancement of zone of inhibition around Imipenem and/or 
Meropenem and/or Ceftazidime toward the EDTA disc when compared 
with the zone of inhibition of corresponding antibiotic disc was interpreted 
as positive for MBL production. 
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COMBINED DISC TEST/DISC POTENTIATION TEST
45
 
Two discs each of 10 µg Imipenem, 10 µg Meropenam and 30 µg 
Ceftazidime were placed on lawn culture of 0.5 McFarland test organism 
seeded on MHA. To one disk of Imipenem, Meropenem and Ceftazidime, 
5 µl of 0.5 M EDTA (930 mg) was added. Plates were kept for incubation 
at the temperature of 37°C for 18-20 hours. After incubation, inhibition 
zone was noted. Organisms which showed increased zone of inhibition by 
7 mm or more around any or all of the three discs with EDTA or showed 
increase in 5-28 mm inhibition around only CAZ-EDTA disc as compared 
to Imipenem, Meropenem and Ceftazidime discs alone, respectively, were 
considered to be MBL producers. A blank disc of EDTA was tested as 
control. 
 
The MBL E test procedure
47
 
MBL E test strips with IMP (4 to 256µg/ml) and IMPE (1to 
64µg/ml) were applied on Mueller-Hinton agar inoculated with test 
organism. The plates were kept for incubation for a time period of 16 to 20 
hrs at a temperature of 35°C. It was reported as metallo β lactamase 
producer if there is reduction of IMP MIC≤ 3 twofold dilutions in the  
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presence of EDTA. Similarly, a "phantom" zone is present between the two 
gradient divisions or distortion of the IP ellipses indicates the presence of 
metallo-ß lactamases. The MICs were read as resistant, intermediate and 
sensitive according to CLSI guidelines (Resistant: MIC ≥16 ug/ml, 
sensitive: MIC≤ 4ug/ml). 
 
MODIFIED HODGE TEST
48
 
MHA plate is streaked with the ATCC Escherichia coli 25922 and 
an imipenem disc is placed in the centre. Imipenem resistant isolates are 
inoculated from the edge of the disc to the periphery of the plate. It is 
incubated overnight and read. Imipenem hydrolyzing strains produce 
distortion on the zone whereas non hydrolyzing zones do not produce any 
effect. 
 
AMP C BETALACTAMASES 
 AmpC β-lactamase produced by Escherichia coli was the first 
bacterial enzyme reported to destroy penicillin. Mutations with stepwise-
enhanced resistance were termed ampA and ampB. Reduced resistance 
caused by mutation in an ampA strain was designated as ampC. There had  
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been many changes in most of the amp nomenclature over the years but the 
designation ampC has persisted. The ampC gene from Escherichia coli was 
reported as well as sequenced in 1981. 
In the structural classification of β-lactamases by Ambler, AmpC 
enzymes was designated in class C, whereas in the functional classification 
scheme by Bush et al, they were designated to group 1.Typically, the 
molecular masses of AmpC enzymes were 34 to 40 kDa and have 
isoelectric points of ≥8.0. They are more active on cephalosporins than 
penicillins. Oxyiminocephalosporins such as cefotaxime, ceftriaxone, 
ceftazidime and monobactams such as aztreonam, Cephamycins such as 
cefotetan and cefoxitin are hydrolyzed by these enzymes. Aztreonam, 
oxacillin and Cloxacillin, however, are good inhibitors. Though 
Cefuroxime, Cefotaxime, Ceftazidime, Ceftriaxone, Cefepime, Aztreonam 
and Piperacillin are weak substrates and weak inducers, they will be 
hydrolyzed if enough enzymes are present
49
. 
Two types of Amp C are present – Plasmid mediated and 
Chromosomal. Klebsiella sps, Salmonella sps and Proteus mirabilis are 
plasmid mediated whereas Citrobacter freundii, Enterobacter cloacae, 
Hafnia alvei, Morganella morganii, and Serratia marcescens. The unique 
feature of Escherichia coli is that it expresses chromosomal Amp C at low  
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levels. Constitutive hyper production or hyperinducibility of AmpC is due 
to mutation in ampD which is the commonest cause of AmpC 
overexpression
50
 
Pseudomonas aeruginosa has three ampD gene, production of 
enhanced AmpC occurs in a stepwise manner. The most common 
resistance mechanism against various β-lactam drugs is the selection of 
mutations leading to the hyper production of chromosomal AmpC. The 
derepressed mutants can be selected in clinical settings expressing resistant 
phenotype. Several such chromosomally mediated Pseudomonas – derived 
cephalosporinases (PDC) with extended-spectrum cephalosporinases 
activities have been reported among Pseudomonas aeruginosa. In addition 
to chromosomal AmpC, the production of plasmid - mediated AmpC 
represents a new threat in the treatment of infection caused by P. 
aeruginosa51. 
 
METHODS TO DETECT AmpC BETA LACTAMASES 
AmpC DISK TEST
52 
 
In a MHA plate, a lawn culture of E. coli ATCC 25922 was made. 
Sterile saline (20µl) was put on the sterile disks (6 mm) which was later  
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inoculated with several colonies of test organism. Cefoxitin disk (almost 
touching) was placed on a fresh inoculated plate. The inoculated disk was 
then placed adjacent to cefoxitin disk and incubated overnight at 35°C. The 
inference was made as follows: 
Flattening or indentation of the cefoxitin inhibition zone in the 
vicinity of the test disk is produced, it is taken as positive test. A negative 
test had an undistorted zone. 
 
Modified Three Dimensional Tests
52
 
Fresh overnight growth of the test organism was transferred from 
Mueller Hinton agar (MHA) to a sterile micro centrifuge tube which was 
weighed previously and to obtain 10-15 mg of bacterial wet weight, it was 
weighed again to determine the weight of bacterial mass. The pellet was 
made by suspending the bacterial mass into the peptone water and 
centrifuged for 15 minutes at 3000 rpm.  The bacterial pellet was 
repeatedly freeze thawed (approximately 10 cycles) to prepare the crude 
enzyme extract.  Mueller Hinton Agar plates were taken and a Lawn 
culture of E. coli ATCC 25922 was made on it. Cefoxitin (30 µg) disk were 
placed on the Mueller Hinton Agar plates. Linear slits (3 cm) were cut 3 
mm away from cefoxitin disk, using sterile surgical blade. The enzyme  
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extract was put in a small circular well which was made at the other end of 
the slit. A total of 30 to 40 µl of extract was loaded in the well at a 10 µl 
increment. The Liquid in the plates were allowed to dry after keeping it 
upright for 5 to 10 minutes and were incubated for 24 hrs at 37°C. The 
presence of AmpC β-lactamases was interpreted and considered a positive 
three-dimensional test when there is enhanced growth of the organism on 
the surface at the point where the slit inserted the zone of inhibition of 
cefoxitin. Three different types of results were recorded according to the 
zone of inhibition of the cefoxitin.  
AmpC producers   - Clear distortion  
Non-AmpC producers  - No distortion  
Indeterminate strains  - Minimal distortion  
 
CEFTAZIDIME IMIPENEM ANTAGONISM TEST (CIAT)
 51, 53
 
In this test, a ceftazidime disk (30 µg) is kept 20 mm away (edge-to-
edge) from an imipenem disk (10 µg) on a Mueller-Hinton agar plate 
which was priorly inoculated with bacterial suspension matching with 0.5 
McFarland standard. The plate was incubated for 24 hrs at 35°C.  A 
cefoxitin disk was used for comparison was kept 20 mm away from the 
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ceftazidime disk. Inducible AmpC beta-lactamase production was 
considered as positive if there is a visible reduction in the zone of 
inhibition around the ceftazidime disk adjacent to the imipenem or 
cefoxitin disks is present. 
 
NON BETA LACTAM INHIBITORS
49
 
One of the best known Amp C inhibitors is boronic acid. Several 
boronic acid derivatives have been added to an empty sterile disc. The disk 
loaded with boronic acid is then placed adjacent to β lactam disc. Yagi et al 
reported that an increase of ≥5mm in the zone of inhibition around a 
ceftazidime or cefotaxime disc already loaded with 300µg of 3 amino 
phenyl boronic acid detects all AmpC varieties. It was negative in 
coproduction of ESBLs and carbapenemases.  
 
CLOXACILLIN COMBINED DISK DIFFUSION TEST (CCDDT) 
54 
The test was performed, to detect both inducible and constitutive 
AmpC. The test was performed by using cefoxitin and ceftazidime 
antibiotic disks with and which were placed at a distance from each other. 
Increase in ≥ 5 mm in the zone diameter for any one of the antimicrobial,  
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when tested in combination with cloxacillin, when compared with its zone 
when it was tested without cloxacillin confirms the AmpC β-lactamase 
production.  
 
DOUBLE DISK SYNERGY TEST (DDST) 
54 
The test was performed by using cefotaxime and ceftazidime disks. 
Between these two discs, a cloxacillin disk was placed at a distance of 10 
mm. If there is synergism between cloxacillin and ceftazidime and/or 
cefotaxime, then it indicates AmpC β-lactamase producers. This test 
detects both inducible and constitutive Amp C inducers as well. 
 
METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS 
Staphylococcus aureus is the most important human pathogen 
present in the external environment and in the anterior nares of 20- 40% of 
adults. It is also seen in the axillae, intertriginous skin folds, the perineum, 
and the vagina
27
.It is responsible for several infections which ranges from 
mild skin and soft tissue infections to severe life threatening infections. 
Originally, penicillin was the drug of choice for the treatment of serious 
Staphylococcus aureus infections. The advent of penicillin resistance in the  
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S. aureus was due to the acquisition of plasmid borne genetic elements 
coding for β lactamase production
27
.  
 Later, penicillinase-resistant, semisynthetic penicillins such as 
oxacillin, methicillin was the drug of choice for these organisms
27
. 
Incorrect use of many antibiotics, intravenous drug abuse, long hospital 
stay, nasal carriage of MRSA is some of the important risk factors for 
MRSA acquisition
55
. In 1961, the MRSA case was first noticed in the 
United Kingdom within a short period of introduction of methicillin into 
clinical practice. In October 1960’s, MRSA was reported 
56, 57
. The latter 
type of resistance is due to the manifestation of different penicillin binding 
protein known as PBP2a which results from the acquisition of a 
chromosomal gene known as mecA. Strains of Staphylococcus aureus 
which express the mecA determinant are called as MRSA (Methicillin 
Resistant Staphylococcus aureus27.  
Infections produced by Methicillin-resistant Staphylococcu saureus 
(MRSA) account for 40-60% of all nosocomial Staphylococcus aureus 
infections in many centers across the world. Since 1970s, MRSA was the 
main cause of healthcare-associated infections. In 1990s, sudden increase 
in the number of MRSA infections was found in populations without prior  
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healthcare contact. This increase has been associated with the recognition 
of new MRSA strains, often called community- associated MRSA (CA-
MRSA) strains
58
. 
MRSA in India 
In India, the significance of MRSA was recognized late. It emerged 
as a major problem in the 80’s and in the 90’s.the incidence of MRSA in 
western part of India is about 25% whereas it is 50% in South India. 
Community Acquired MRSA has been reported more in India
56
. 
 
MECHANISM OF RESISTANCE 
The chromosomally localized mecA gene is responsible for 
methicillin resistance. Penicillin binding protein 2a synthesis requires 
mecA gene. Penicillin binding protein are membrane bound enzyme which 
catalysis the transpeptidation reaction which is responsible for cross linking 
of peptidoglycan chains.PBP2a has low affinity for all beta lactam 
antibiotics .it substitutes other PBPs which enables Staphylococcus to 
survive exposure to high concentration of beta lactam antibiotics
27
. 
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Four different SCCmec elements have been recognized. SCCmec 
type I, II and III is associated with Health care associated MRSA (HA-
MRSA). Community associated MRSA tend to carry Type IV element.CA-
MRSA have been typed as USA 300 and 400 with the help of pulse field 
gel electrophoresis.CA – MRSA has a characteristic antibiotic 
susceptibility pattern, carries specific virulence factor such as Panton –
valentine leukocidin and specific SCC mec type IV
59
. 
 
MRSA DETECTION IN LABORATORY
27
 
Staphylococcus aureus is identified by its colony morphology. Gram 
stain shows the presence of gram positive cocci in clusters .It also gives 
positive catalase and coagulase test. Phenotypic and genotypic methods are 
used to detect Staphylococcus aureus. 
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METHODS TO DETECT MRSA 
1. DISC DIFFUSION METHODS
60
 
Cefoxitin disc diffusion test 
 Cefoxitin belongs to cephamycin is a potent inducer of mecA gene. 
Several studies have reported that cefoxtin disc diffusion test has good 
results in determining mecA gene than the oxacillin disc diffusion. The test 
is performed by placing 30µg of cefoxitin disc in the Mueller Hinton Agar 
plate without NaCl supplementation. The plate is kept in a incubator at the 
temperature of 37˚c. The zone of inhibition is determined after 24 hrs and 
the zone size is interpreted as susceptible ≥21mm, resistant ≤21 mm as per 
CLSI guidelines. 
 
2. Oxacillin screen agar method 
Oxacillin screening is done by using 6 mg/ml of oxacillin in Mueller 
Hinton agar with 4% NaCl. All methicillin resistant strains were confirmed 
by this method. Plates were incubated at 30˚C. The strains which grow in 
this medium were considered as Methicillin resistant Staphylococcus 
aureus (MRSA). 
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3. MIC determination
61,62
 
(i) Agar dilution method 
4-5 discrete colonies were emulsified onto 4-5 ml of nutrient broth 
which is adjusted to 0.5 McFarland standard.0.0001ml is used as the final 
inoculum. The concentration of oxacillin used is 32µg-0.015µg/ml. After 
drying, 1µl of inoculum is inoculated in the plates using a calibrated 
platinum loop. The plates are incubated at 37˚cfor 24hrs.MIC is the lowest 
concentration at which no visible growth occurs. Susceptible ≤2µg/ml, 
resistant ≥4µg/ml. 
 
(ii) Broth dilution method 
To a Mueller Hinton broth with 4%NaCl, serial dilution of oxacillin 
is added. Few colonies of Staphylococcus aureus are emulsified into fresh 
peptone water and adjusted to match 0.5 McFarland standard which is used 
as inoculum. It is incubated at 33-35° c or 24 hrs. Oxacillin MIC < 2µg/ml, 
Resistant > 2µg/ml. 
 
 
(iii) E test 
 The E test, a quantitative method for testing susceptibility of 
antibiotic applies for both antibiotic diffusion and dilution into the 
medium. It contains a thin inert carrier strip which has a predefined stable  
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antimicrobial gradient present on it. When this E strip is placed in Mueller 
Hinton agar plate inoculated with test organism, there is prompt release of 
the drug into the medium. After incubation, a symmetrical inhibition 
ellipse is produced. The intersection between the carrier strip and the edge 
of inhibitory zone denotes the MIC value. 
 
(iv) Latex agglutination test for detection of PBP 2a
63
 
 200µl of extraction reagent is taken into which a loopful of bacterial 
cells is added. It is then subsequently lysed by boiling for 3 min and cooled 
to room temperature. To 200µl of lysate 50µ l of another extraction reagent 
is added and mixed well. It is then centrifuged at 1500rpm.40µ l of 
supernatant is taken and used as for testing agglutination with sensitized 
latex particles. The card is rotated for 3 min. the resulting agglutination 
patterns are read. 
 
NEWER METHODS 
Screening test 
Mannitol salt agar cefoxitin screening medium
64
 
Mannitol salt agar plates with cefoxitin concentration of 2, 3 or 
4mg/ml is prepared. Fresh overnight cultures are used to prepare inoculum 
which matches 0.5 Mc Farland’s standard. The test inoculum is streaked  
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onto the agar and kept for incubation at the temperature of 35 – 37˚ c for 48 
hrs. The results are interpreted at 18 to 48hrs. Positive results are taken 
when there is any visible growth in the medium. 
 
CHROMagar MRSA
65
 
 It is used for direct identification of MRSA from clinical specimens. 
When the specimen is applied to the agar, MRSA appears as light mauve to 
mauve colonies after 16-18 hrs of incubation. Other colonies will grow as 
white or beige or has poor growth. 
 
GENOTYPIC METHODS 
Multiplex PCR for MRSA detection of mec A and fem B genes. 
Coag genes, ccr genes, nuc genes, toxin genes. 
 
1. Real time PCR 
MRSA isolates are detected directly from blood culture bottles using 
real time PCR assays.  Based on melting curve analysis, the assay 
differentiates into clusters. 
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2. Pulsed Field Gel Electrophoresis
66,67
 
From an overnight grown culture of a single colony, a bacterial 
pellet is processed and the restriction fragments are separated on the gel. 
Gel is stained with ethidium bromide. The photo is taken under Ultra violet 
light. Strain relatedness among CA-MRSA and HA-MRSA isolates can be 
investigated. 
 
 
3. Multi locus Sequence Typing(MLST)
66 
The clonal evaluation of MRSA is detected by MLST. Sequential 
analysis from 7 Staphylococcus aureus shows the housekeeping genes as 
follows i.e. aroE, arcC, glpF, gmK, pt, tpi and yqil. Each isolate is defined 
by all the alleles of the seven genes. This results in an allele profile / gene 
sequence type (ST). 
 
4. Microarray Analysis
68
 
Multiplex PCR products can be used as hybridization samples. After 
hybridization at the test site of the microarray, detection of fluorescence is 
done automatically by the instrument images of the array. Automatically 
captured image is then analysed using the image analysis software of the 
instrument. 
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MANAGEMENT OF INFECTION WITH ESBL – PRODUCING 
ORGANISMS 
In vitro, cephamycins and carbapenems are sensitive to strict ESBL 
producers showed little resistance if any inoculum effect with these agents. 
When the inoculum size is raised from 10
5
 to 10
7
 organisms, even both 
Piperacillin / Tazobactam and cefepime shows reduced sensitivity to TEM 
and SHV type ESBLs producers. 
 
Inspite of the use of a standard inoculum, cefepime is resistant to 
CTX –M type and OXA type ESBLs strains.  
 
Inhibitor- resistant β lactamases 
                The tazobactam and piperacillin/tazobactam combination are still 
sensitive to inhibitor –resistant TEM variants whereas clavulanic acid and 
sulbactam are resistant to it. 
 
AmpC  
AmpC producers are usually resistant to cephamycins and oxyimino-
beta lactams but they are sensitive to carbapenems but diminished porin 
expression makes them resistant to carbapenem as well. 
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Management of MRSA infections 
The drug of choice for serious infections caused by Methicillin 
resistant Staphylococcus aureus is Vancomycin. MRSA infections can be 
treated by Vancomycin and Teicoplanin which are glycopeptide antibiotics. 
Teicoplanin has a longer half-life when compared to vancomycin. For 
systemic infections, intravenous route is preferred since the glycopeptide 
antibiotics have poor oral absorption. Due to the inconvenient route of 
administration of vancomycin, treatment of MRSA infection can be 
difficult. Many newly discovered MRSA strains shows resistance even to 
vancomycin and teicoplanin. These are called as Vancomycin Intermediate 
resistant Staphylococcus aureus. Daptomycin, Linezolid, tigecycline and 
Quinupristin/Daltopristin are the some drugs used to treat vancomycin 
resistant infection. 
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MATERIALS AND METHODS 
This cross sectional study was done for a period of one and a half 
year from January 2013 to August 2014 to study the bacterial isolates from 
patients with CSOM at Government Kilpauk Medical College and 
Hospital, Chennai. A total of 212 samples collected from both sexes in all 
age groups were studied during this period. 
 
INCLUSION CRITERIA 
1. Clinically diagnosed Chronic Suppurative Otitis Media cases of 
various age groups and both sexes were included. 
 
2. Patients who were not on antibiotic (both systemic and topical) 
treatment for minimum of 1 week prior to sample collection.  
 
EXCLUSION CRITERIA 
1. Nonbacterial pathogens causing CSOM.  
2. Patients with other middle ear infections were excluded. 
3. Patients having discharge for less than 3 weeks. 
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SAMPLE COLLECTION
69 
Pus samples from ear discharge were collected under aseptic 
conditions using two sterile cotton swabs after obtaining informed content. 
The external ear was first cleaned using sterile cotton swabs soaked in 
sterile physiological saline. After cleaning, the exudates were collected 
using sterile cotton swabs using aural speculum. 
 
SPECIMEN TRANSPORT 
Samples were sent immediately to microbiology laboratory without 
delay.  
 
SAMPLE PROCESSING 
DIRECT GRAM STAIN 
One swab was used to do direct gram stain study for the presence of 
pus cells, epithelial cells and bacteria.  
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CULTURE 
Second swab was used for inoculation of Nutrient agar, 5% Sheep 
blood agar and Mac Conkey agar. To differentiate pathogens from 
commensals, standard microbiological methods were followed. The 
importance of the isolates obtained was assessed on the basis of clinical 
history, presence of pus cells in direct gram stain, pure growth on culture. 
 
ANTIBIOTIC SUSCEPTIBILITY TESTING70 
Antibiotic sensitivity testing was performed on Mueller Hinton agar 
using Kirby Bauer disk diffusion method. Interpretation of the results was 
done by measuring the sizes of the zone of inhibition according to CLSI 
guidelines 2013(M100-S23). 
Escherichia coli                    -       ATCC 25922. 
Pseudomonas aeruginosa  - ATCC 27853. 
Staphylococcus aureus           -     ATCC 25923  
were used as quality control strains. 
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TURBIDITY STANDARD FOR INOCULAM PREPARATION 
For a susceptibility test, density of the inoculum is standardized by a 
BaSO4 turbidity standard, which is equal to 0.5 McFarland standard or its 
optical equivalent (e.g., latex particle suspension), should be used. 
 
Inoculum preparation 
Isolated colonies (approx. 3-5) belonging to similar morphological 
type should be taken and mixed in about 4-5 ml of a suitable broth medium 
in a sterile test tube. The broth culture is incubated at 35˚c until it attains 
0.5 McFarland turbidity medium. This suspension corresponds to150 
million organisms/ml. 
 
Method of inoculation of test plates 
The turbidity of the test medium was adjusted and  it was inoculated 
within 15 minutes into the plates. A sterile cotton swab is immersed into 
the suspension and it is pressed along the sides of the tube to remove the 
excess inoculum from the swab. The swab is then streaked onto a 
previously dried Mueller Hinton agar plate. This procedure is repeated 2-3  
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times by rotating the plate 60˚c so that the inoculum is evenly distributed 
onto the plate. Finally, the rim of the plate is swabbed. Within 15 minutes, 
the antibiotic discs are impregnated onto the plate. The discs should be 
pressed firmly to confirm complete contact with the surface of the agar. It 
is ensured that the discs are placed 24mm from center to center. The plate 
is inverted and kept in the incubator within 15 minutes after the application 
of the drugs. The plate is examined after 16-18 hrs of incubation. The zone 
of inhibition will be uniformly circular with a confluent lawn of growth if 
the inoculum was correct. The diameter of the inhibition zone are 
calculated with the help of sliding calipers or rulers and interpreted as per 
CLSI guidelines 
 
METHODS TO DETECT EXTENDED SPECTRUM BETA 
LACTAMASES
32, 34, 41
 
Quality control 
Quality controls were performed using 
Escherichia coli   ATCC 25922  - Negative control 
Klebsiella pneumoniae   ATCC 700603  - Positive control. 
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Disk diffusion methods 
Disk diffusion test was done for all Enterobacteriaceae isolates 
against cefotaxime (30 µg), ceftriaxone (30 µg),cefpodoxime (10 µg) and 
ceftazidime (30 µg) antibiotic disks for the screening of the isolates for 
potential ESBL production. Overnight incubation was done at 37˚c after 
which the zone size was read as per CLSI recommendations for ESBL 
screening criteria. 
 
Phenotypic confirmatory tests or disc potentiation test 
This test was done for all enterobacteriaceae isolates against 
ceftazidime (30 µg) antibiotic discs with and without clavulanic acid (10 
µg). These discs were placed on a Mueller –Hinton agar plate inoculated 
with bacterial suspension equivalent to 0.5 McFarland standards. Overnight 
incubation was done at 37°C after which the result was interpreted as 
follows: 
If the zone diameter of ceftazidime with clavulanic acid was 
increased ≥ 5 mm when compared with ceftazidime alone was taken as 
positive for ESBL production. 
 70 
 
 
 
MIC determination - Agar dilution method 
Media Preparation 
Freshly prepared and autoclaved Mueller Hinton agar was allowed to 
cool in a 50 ˚c water bath. Preparation of serial dilution of 3
rd
 generation 
cephalosporin (ceftazidime, cefotaxime) was prepared in sterile distilled 
water which gives a final concentration of 2µg – 2048µ g/ml of agar. The 
drugs are added to the medium at 50˚c.It was mixed well and poured onto 
sterile petri plates. Test medium without the antibiotic was used as control 
plate for each series of test. 
 
Preparation of Inoculum 
3-5 well isolated colonies belonging to same morphological type 
should be taken and mixed in about 4-5 ml of a suitable broth medium in a 
sterile test tube. The broth culture was incubated at 35˚c until it attains 0.5 
McFarland turbidity medium. This suspension corresponds to150 million 
organisms/ml. 
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Test plate inoculation 
        0.003ml of inoculum was added to appropriate quadrants divided on 
the plates of various concentrations and incubated at 37 c for 16-20 hrs. 
Minimum inhibitory concentration is the lowest concentration at which no 
visible growth occurs. Various concentration of cephalosporin with 4µg/ml 
of clavulanic acid ranging from 0.5µg to 2048µg/ml of agar was tested with 
isolates and the MIC was obtained. 
DETECTION OF ESBL PRODUCERS BY POLYMERASE CHAIN 
REACTION (PCR)
 71 
DNA Extraction methods 
DNA extraction was done with the help of DNA Purification kit 
(PureFast Bacterial Genomic DNA purification kit) and polymerase chain 
reaction master mix. 
 Constituents of Master Mix 2X  
1. Taq DNA Polymerase - 2Units. 
2. 10X Taq reaction buffer 
3. 2mM Magnesium Chloride. 
4. 10mMdNTPs mix - 1µl. 
5. Polymerase Chain Reaction additives. 
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Agarose for the purpose of Gel Electrophoresis - Agarose, 
50XTAE buffer,6Xgel loading buffer, Ethidium bromide were used. 
Procedure of DNA Extraction 
1. Pellet was suspended in 200µl of Phosphate Buffer Saline (PBS). 
2. Add 50µl of lysosome and incubated at37 c for 15 min. 
3. Mix lysis buffer(400µl) and  proteinase K(40µl). 
4. Incubate the mixture in a water bath at 70 c for ten minutes. 
5. The whole lysate was transferred into pure fast spin column. It is 
then kept in centrifuge at 10000rotations/min for about 1 min. 
6. Discard flow through and 500µl of wash buffer-1 was added and  
placed in centrifuge for 1 min  
7. Discard flow through 0.5ml of wash buffer – 2 and kept in centrifuge 
for 1min. This procedure was done again and washed for one more 
time. 
8. Discard flow thorough. To remove the residual ethanol column was 
centrifuged for 2 min 
9. Add 100µl of elution buffer to elute DNA and then centrifuged for 1 
min. 
10. Extracted DNA quality and quantity was checked by loading in 1% 
agarose gel and 1µl of extracted DNA was used for amplification by 
PCR. 
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PRIMERS 
CTX-M-14 
Product size - 120bp  
5'-TTATGCGCAGACGAGTGCGGTG-3'  
5'-TCACCGCGATAAAGCACCTGCG-3' 
SHV-12 
Product size- 276bp  
5'-CGCCGCCATTACCATGAGCGAT-3'  
5'-ACCCGATCGTCCACCATCCACT-3' 
TEM primer 
Product size - 148bp  
5’-CCAAACGACGAGCGTGACACCA-3’  
5’-AGCGCAGAAGTGGTCCTGCAAC-3’ 
Procedure of Polymerase Chain Reaction 
[25microliters of Master mix has 10X Taq buffer, 2mM Magnesium 
Chloride. 0.4mMdNTPs mix, and 2UProof reading Taq DNA Polymerase] 
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1. Reaction was done as follows: 
In PCR vial 
Components Quantity 
Master Mix 25µl 
Forward Primer(3pmoles/µl) 2.5µl 
Primer – Reverse(3pmoles/µl) 2.5µl 
Genomic DNA 5µl 
nuclease free water 18µl 
Total volume 50µl 
 
2. Mix and spin down briefly and gently. 
3. It was kept into Polymerase Chain Reaction machine and programmed 
in the following manner: 
 
Initial denaturation was done at 95 c for 3 minutes. 
Denaturation - 95˚ c for 30 seconds. 
Annealing       - 55˚ c for 30 seconds.  35 cycles 
Extension          - 72˚ c for 30 seconds. 
Final extension  - 72˚c for 5 minutes. 
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Loading 
1. Prepare 2% agarose gel. [2grams of agarose was added to 100ml of 
1x TAE buffer] 
2.  8µl of 6X Gel loading dye is added to each PCR vial and 5 
microliters of PCR sample is loaded. 
3.  Electrophoresis is done at 50V until the dye reaches 3/4
th
 of 
distance and look for bands in Ultraviolet Transilluminator. 
 
PREPARATION OF AGAROSE GEL ELECTROPHORESIS 
1. Preparation of 2% agarose was done as follows.  2grams of agarose 
is mixed with 100ml of 1X TAE buffer and it was liquefied by 
heating in a microwave oven. 
2.       Around 60ºC, 5µl of Ethidium bromide was added to agarose gel.  
3. Gently pour the agarose solution which was warm into the gel 
platform.  
4. Until the agarose gets solidified, the gel was not disturbed.  
5. The submarine gel tank was filled with 1XTAE buffer.  
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6. The gel platform was kept inside tank with caution and its 
buffer level was not allowed to exceed 0.5cm above the gel. 
7. With10µl HELINI 100bp DNA Ladder, PCR Samples and gel 
loading dye were added. 
8. Until the dye reaches 3/4
th
 distance of the gel. At 50Velectrophoresis 
was done.  
9. The Gel was observed in Ultraviolet Transilluminator and the pattern 
of bands was detected. 
 
TESTS TO DETERMINE METALLO BETA LACTAMASES 
AMONG NON FERMENTERS 
SCREENING FOR MBLS 
Imipenem: 10µg (IPM) and Ceftazidime: 30 µg (CAZ) resistant 
Pseudomonas aeruginosa isolates was taken for screening MBL production.   
Antibiotic sensitivity was done by the Kirby-Bauer disc diffusion method 
as recommended by CLSI. 
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CONTROLS 
Pseudomonas aeruginosa (blaVIM and blaIMP positive) – positive 
control. 
Pseudomonas aeruginosa ATCC 27853 - Negative control. 
 
CONFIRMATION OF MBL PRODUCTION 
All isolates positive for MBL production by screening test were 
subjected to: 
 
COMBINED DISC TEST/DISC POTENTIATION TEST
45
 
A lawn culture of 0.5 McFarland equivalent suspension of test 
organism was done in Mueller Hinton Agar plate. Two disc of Ceftazidime 
30µg/Imipenem 10µg were placed in the plate with centre to centre  at a 
distance of 25mm. 5 µl of 0.5 M EDTA (930 mg) was pipetted on one disk 
of Imipenem and Ceftazidime. After incubation at 37°C for 18-20 hours, 
increased zone of inhibition by 7 mm or more around any or all of the two 
discs with EDTA or increase in 5-28 mm inhibition around only CAZ- 
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EDTA disc when compared to Imipenem, Ceftazidime discs alone, 
respectively, were considered to be MBL producers. 
 
METHODS TO DETECT AMP C PRODUCTION 
SCREENING OF AMP C PRODUCTION 
All isolates were screened for cefoxitin susceptibility and those 
which had a zone diameter of ≤ 18 mm were suspected to be AmpC 
producers. 
 
AMPC DISK TEST
52 
In a MHA plate, a lawn culture of E. coli ATCC 25922 was made. 
Sterile saline (20µl) was put on the sterile disks (6 mm) which was later 
inoculated with several colonies of test organism. Cefoxitin disk (almost 
touching) was placed on a fresh inoculated plate. The inoculated disk was 
then placed adjacent to cefoxitin disk and incubated overnight at 35°C. The 
inference was made as follows: 
Flattening or indentation of the cefoxitin inhibition zone in the 
vicinity of the test disk is produced was taken as positive. A negative test 
had an undistorted zone. 
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CEFTAZIDIME IMIPENEM ANTAGONISM TEST (CIAT)
51, 53
 
AmpC production was also confirmed by Ceftazidime - imipenem 
antagonism test (CIAT) (for inducible/chromosomal AmpC detection). In 
the disk antagonism tests, the test strain was exposed to disks of 
ceftazidime-imipenem which were placed at a distance. Flattening of the 
radius of the zone of inhibition produced on the side nearest to the 
imipenem disk indicated inducible AmpC production. 
 
TESTS TO DETECT METHICILLIN RESISTANT 
STAPHYLOCOCCUS AUREUS 
CEFOXITIN DISC DIFFUSION TEST
60
 
The test was performed by placing 30µg of cefoxitin disc in the 
Mueller Hinton Agar plate without NaCl supplementation inoculated with 
test organism. The plate was kept in incubator at a temperature of 37˚c. The 
zone of inhibition was determined after 24 hrs and the zone size was 
interpreted as 
          Susceptible: ≥21mm  
Resistant : ≤ 21 mm 
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STATISTICAL ANALYSIS 
The test outcome was observed, recorded and analysed. The data that 
were analysed was presented in the form of statistical tables, pie charts and 
histograms if necessary in appropriate places. P values were calculated by 
Chi –Square test. The data were documented and studied in detail. The 
documented data was further discussed in detail and compared with other 
similar studies published in reputed scientific journals. 
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RESULTS 
Patients with Chronic Suppurative Otitis Media(CSOM) attending  
ENT OP at Government Kilpauk Medical College  and Hospital, Chennai 
were studied for Extended Spectrum Beta Lactamases(ESBL), Metallo beta 
lactamases(MBL), AmpC beta lactamases and Methicillin Resistant 
Staphylococcus aureus(MRSA) . The study was done between January 
2013 to August 2014. 212 patients with CSOM were studied and 173 
bacterial isolates were isolated, identified and analysed for their antibiotic 
sensitivity pattern. Resistant isolates were identified and studied for 
Extended Spectrum Beta Lactamases(ESBL), Metallo beta lactamases 
(MBL), AmpC beta lactamases and Methicillin Resistant Staphylococcus 
aureus (MRSA) by various methods. 
The observations were recorded and analysed. The results were as 
follows: 
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TABLE NO: 1 – AGE DISTRIBUTION (n=212). 
AGE(YEARS) MALE FEMALE PERCENTAGE 
0-10 10 4 14(6.60%) 
11-20 19 14 33(15.57%) 
21-30 25 30 55(25.94%) 
31-40 18 31 49(23.11%) 
41-50 15 12 27(12.73%) 
51-60 13 8 21(9.91%) 
61-70 8 3 11(5.18%) 
71-80 2 0 2(0.94%) 
Total 110 102 212 
 
Males and females within the age of 21- 30 years suffered from 
Chronic Suppurative Otitis Media when compared to other age groups. In 
our study, there was no statistical significance (p=0.557) in the age group 
causing CSOM.CSOM was equally distributed among males and females 
of all age groups. 
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TABLE NO:  2 – GENDER DISTRIBUTION (n=212) 
GENDER PERCENTAGE 
Males 110(51.88%) 
Females 102(48.11%) 
 
Percentage of males with CSOM was 52% whereas the percentage of 
females was 48%. 
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TABLE NO: 3 – RISK FACTORS OF PATIENTS (n=212) 
Risk Factors % 
Annual Income of self/guardian 
≥ 100000 17(8.01%) 
100000 -50000 71(33.49%) 
≤ 50000 124(58.49%) 
Education of self/parents 
Illiterate 60(28.30%) 
SSC & below 103(48.59%) 
HSC & Above 49(23.11%) 
Habit of ear cleaning 
no habit 154(72.64%) 
cleans ear 58(27.35%) 
 
Out of 212 patients, 17(8.01%) had the annual income of ≥10000 
whereas only 124(58.49%) had annual income of less than 50000. About 
60(28.30%) were illiterates and 154(72.64%) did not have regular ear 
cleaning habits. 
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TABLE NO: 4 - SYMPTOMS OF CSOM (n=212) 
 
 
Symptoms % 
Discharge only 112 (52.83%) 
Discharge with deafness 51(24.06%) 
Discharge with earache 28(13.21%) 
Discharge ,earache and deafness 21(9.90%) 
Total 212 
 
Out of 212 patients with CSOM, 112(52.83%) had the presenting 
complaint of only discharge in the ear whereas 21(9.90%) presented with 
discharge, earache and deafness. 
TABLE NO: 5 – SMEAR vs. CULTURE (n=212) 
 
Direct Smear 
Positive 
Direct Smear 
Negative 
Culture Positive 153(72.17%) 4(1.89%) 
Culture Negative 0 55(25.94%) 
 
153(72.17%) patients showed both direct smear and culture 
positive.4 (1.89%) were direct smear negative and culture positive.  
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55(25.94%) were both direct smear and culture negative. None of them 
were direct smear positive and culture negative. 
TABLE NO: 6 - CULTURE POSITIVITY (n=212) 
Culture Positive 157(74.06%) 
Culture Negative 55(25.94%) 
Total 212 
 
Number of swabs that were culture positive was 157(74.06%) and 
number of sterile pus swabs was 55(25.94%). 
TABLE NO: 7 - PURE vs.  MIXED GROWTH (n=157) 
ORGANISM PERCENTAGE 
Monomicrobial 141(89.80%) 
Polymicrobial 16(10.19%) 
 
Majority of cases 141(89.80%) showed monomicrobial infection and 
16(10.19%) showed polymicrobial infection. 
 CULTURE POSITIVITY (n=212)
Culture Positive
10%
PURE vs.  MIXED GROWTH (n=157)
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TABLE NO: 8 - GRAM POSITIVE Vs. GRAM NEGATIVE 
(n=173) 
 
 
ORGANISM PERCENTAGE 
Gram negative bacilli 113(65.32%) 
Gram positive cocci 60(34.68%) 
Total 173 
 
Out of 173 isolates from 212 patients, total number of Gram Positive 
cocci was 113(65.32%) and total number of Gram Negative bacilli was 
60(34.68%) 
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TABLE NO: 9- DISTRIBUTION OF ORGANISMS (n=173) 
 
 
ORGANISMS % 
Pseudomonas aeruginosa 80(46.24%) 
Staphylococcus aureus 46(26.59%) 
Klebsiella pneumoniae 25(14.45%) 
Coagulase Negative 
Staphylococcus aureus 9(5.20%) 
Proteus mirabilis 7(4.05%) 
Enterococcus faecalis 5(2.89%) 
Escherichia coli 1(00.58%) 
Total 173 
 
Out of 173 isolates, isolated from 212 patients with CSOM, 
Pseudomonas aeruginosa 80(46.24%) was the most common organism 
isolated in Gram Negative bacilli followed by Klebsiella pneumoniae 
25(14.45%). Staphylococcus aureus 46(26.59%) was the common 
organism isolated among the Gram Positive cocci.  
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TABLE NO: 10 – ANTIBIOTIC SENSITIVITY OF GRAM 
NEGATIVE ISOLATES (n=113) 
Antibiotics 
Pseudomonas 
aeruginosa 
(n=80) 
Klebsiella pneumonia 
(n=25) 
Proteus 
mirabilis(n=7) 
Amoxycillin Not Tested 7(28.00%) 2(28.57%) 
Amoxycillin -
clavulinic acid 
63(78.75%) 17(68%) 6(85.71%) 
Cefoxitin 72(90%) 21(84%) 7(100%) 
Cephalexin 52(65%) 13(52%) 4(57.14%) 
Cefotaxime 74(92.50%) 15(60%) 7(100%) 
Ceftazidime 74(92.50%) 15(60%) 7(100%) 
Amikacin 77(96.25%) 20(80%) 6(85.71%) 
Gentamicin 59(73.75%) 14(56%) 3(42.85%) 
Ciprofloxacin 58(72.50%) 12(48%) 3(42.85%) 
Ofloxacin 76(95%) 18(72%) 6(85.71%) 
Piperacillin –
Tazobactam 
78(97.50%) 25(100%) 7(100%) 
Imipenem 80(100%) 25(100%) 7(100%) 
  
 All gram Negative bacilli isolates showed 100% sensitivity to 
imipenem. Klebsiella pneumoniae and Proteus mirabilis showed 100% 
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sensitivity to Piperacillin/Tazobactam but Pseudomonas aeruginosa 
showed 78(97.50%) sensitivity to Piperacillin/Tazobactam. 
 Pseudomonas aeruginosa showed 77(96.25%) and 76(95%) 
sensitivity to amikacin and ofloxacin respectively where as Proteus 
mirabilis showed 6(85.71%) sensitivity to amikacin. 
 Amoxycillin showed less than 30% sensitivity to Klebsiella 
pneumoniae and Proteus mirabilis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 94 
 
 
CHART  VII 
 
   NT - Not Tested 
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TABLE NO: 11 – ANTIBIOTIC SENSITIVITY OF GRAM 
POSITIVE ISOLATES (n=60). 
Antibiotics 
Staphylococcus 
aureus(n=46) 
Coagulase Negative 
Staphylococcus 
aureus(n=9) 
Enterococcus 
faecalis(n=5) 
Amoxycillin 11(23.91%) 3(33.33%) Not Tested 
Erythromycin 31(67.39%) 5(55.55%) 2(40%) 
Doxycycline 34(73.91%) 7(77.77%) 3(60%) 
Cephalexin 33(71.73%) 6(66.66%) Not Tested 
Cefotaxime 40(86.95%) 8(88.88%) Not Tested 
Amikacin 41(89.13%) 8(88.88%) 4(80%) 
Gentamicin 29(63.04%) 6(66.66%) 2(40%) 
Ciprofloxacin 28(60.86%) 5(55.55%) 2(40%) 
Ofloxacin 40(86.95%) 8(88.88%) 4(80%) 
Co-trimaxazole 20(43.44%) 4(44.44%) 2(40%) 
Vancomycin 46(100%) 9(100%) 5(100%) 
Linezolid 46(100%) 9(100%) 5(100%) 
Cefoxitin 37(80.43%) 7(77.77%) Not Tested 
 
All the Gram Positive cocci were 100% sensitive to Vancomycin and 
Linezolid. Staphylococcus aureus and Coagulase Negative Staphylococcus 
aureus showed 89.13% and 86.95% sensitivity to amikacin to Ofloxacin  
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respectively. Staphylococcus aureus showed sensitivity of 86.95% and 
71.73% to cefotaxime and cephalexin respectively. 
Out of 5 Enterococci faecalis, 80% were sensitive to both Ofloxacin 
and amikacin. 
TABLE NO: 12– SCREENING TEST FOR ESBL 
Gram Negative isolates 
Resistant to ceftazidime 
& cefotaxime 
Klebsiella pneumoniae 
(n=25) 10(40%) 
Pseudomonas aeruginosa 
(n=80) 6(7.5%) 
 
          Out of 113 isolates, 10 Klebsiella pneumoniae and 6 Pseudomonas 
aeruginosa were resistant to both drugs. 
All the 10 isolates were subjected to phenotypic confirmatory test 
/Disc Potentiation test and MIC reduction test to detect the presence of 
ESBL Production .The 6 resistant Pseudomonas aeruginosa isolates were 
subjected to Disc Potentiation test with EDTA test for MBL detection. 
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TABLE NO: 13 – ESBL PRODUCERS BY PHENOTYPIC 
CONFIRMATORY TEST (n=33) 
 
Enterobacteriaceae 
Phenotypic Confirmatory Test – 
Positive 
33 10(30.30%) 
 
By the phenotypic confirmatory method, all 10 Klebsiella 
pneumoniae isolates were identified as ESBL producers 
TABLE NO 14–MINIMUM INHIBITORY 
CONCENTRATION OF ISOLATES TOCEFTAZIDIME  
(µg/ml) (n=10) 
Isolate 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048 
Klebsiella 
pneumoniae 
0 0 0 0 3 2 2 0 0 0 2 1 0 
 
Minimum inhibitory concentration of   isolates to Ceftazidime for 
the ESBL producing organism in the study was between 8(µg/ml) of agar 
to 1024(µg/ml) of agar. 
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TABLE NO: 15- MIC ISOLATES TO CEFTAZIDIME 
WITH CLAVULINIC ACID (n=10) 
Isolate 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048 
Klebsiella 
pneumoniae 
3 2 2 0 0 0 2 0 1 0 0 0 0 
 
Minimum inhibitory concentration of isolates to Ceftazidime for the 
ESBL producing organism in the study was between 0.5(µg/ml) of agar to 
128(µg/ml) of agar in presence of 4µg/ml clavulanic acid in the agar 
showing reduction in ≥3 doubling dilution. 
 
TABLE NO - 16: SCREENING OF MBL (n= 80) 
PSEUDOMONAS AERUGINOSA 
Antibiotics Sensitive Resistant 
Ceftazidime 74(92.5%) 6(7.5%) 
Imipenem 80(100%) 0 
 
All the Pseudomonas aeruginosa isolates resistant to Ceftazidime and 
imipenem were screened as probable MBL producers. Thus out of 80 isolates, 6 
isolates were resistant to Ceftazidime whereas all the Pseudomonas aeruginosa 
isolates showed 100% sensitivity to imipenem. 
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TABLE NO – 17: MBL Detection (n=6) - Disc Potentiation 
test with EDTA 
Ceftazidime – EDTA Test 
No of Isolates Positive Negative 
6 1(16.66%) 5(83.33%) 
 
By Ceftazidime – EDTA Test method, out of 6 isolates 1 (16.66%) was 
found to be MBL producer. Whereas by imipenem –EDTA method none of them 
were MBL producing. 
TABLE NO: 18-- AMP C PRODUCERS AMONG GRAM 
NEGATIVE BACILLI (n=113) 
Gram Negative Bacilli % 
Enterobacteriaceae 3(2.65%) 
Pseudomonas aeruginosa 6(5.30%) 
Total 9(7.96%) 
 
By AmpC disk test and ceftazidime -imipenem antagonism test, 
9(7.96%) were found to be Amp C producers 
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TABLE NO: 19 GENE IDENTIFICATION IN ESBL 
POSITIVE ISOLATES OF TEM, SHV and CTX-M. 
Organism No. tested TEM 
Positive 
SHV 
Positive 
CTX-M 
Positive 
Klebsiella 
Pneumoniae 
10 3(30%) 4(40%) 3(30%) 
 
All the Klebsiella pneumoniae isolates that were confirmed as ESBL 
producers by phenotypic confirmatory test were subjected to PCR for 
TEM, SHV and CTX-M gene identification. Out of 10 isolates subjected to 
PCR, 3(30%) were positive for TEM gene, 4(40%) and 3(30%) were 
positive for SHV and CTX-M genes respectively. 
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TABLE NO: 20 - MRSA DETECTION IN 
STAPHYLOCOCCUS AUREUS BY CEFOXITIN DISC 
DIFFUSION METHOD (n=46) 
Staphylococcus aureus % 
MSSA ≥ 21mm 37(80.43%) 
MRSA ≤ 21mm 9(19.56%) 
Total 46 
 
Out of 46 Staphylococcus aureus, 9(19.56%) were MRSA positive 
by cefoxitin disc diffusion method. 
TABLE NO: 20 a – DETECTION OF METHICILLIN 
RESISTANT IN CONS (n=9) 
CONS – MR % 
MS – CONS ≥ 25mm 7(77.77%) 
MR – CONS ≤ 24mm 2(22.22%) 
Total 9 
 
By cefoxitin disc diffusion method, out of 9 Coagulase Negative 
Staphylococcus aureus isolated, 2(22.22%) were Methicillin Resistant 
CONS. 
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TABLE NO -21:  OUTCOME OF THE STUDY (n=189) THE 
REMAINING 23 LOST FOLLOW UP 
Outcome No (%) MRSA ESBL MBL 
Non 
ESBL/MBL/Amp 
C/MBL 
Recovered 169 
(89.41%) 
9  
(5.32%) 
7 
(4.14%) 
0 153          
(90.53%) 
Operated 20 
(10.5%) 
0 3    
(15%) 
1     
(5%) 
16                 
(80%) 
 
The outcome was noted in 189 cases only and the remaining lost 
follow up .out of 189 cases recovery was seen in 169(89.41%) and 
9(5.32%) were MRSA Positive, 7(4.14%) were ESBL positive and the 
remaining 153(90.53%) did not harbor any ESBL/MBL/AmpC/MRSA 
producers. 
20(10.5%) of them were operated for CSOM, out of them 3(15%) 
were ESBL positive and  1(5%) was MBL positive. 16(80%) of them were 
non ESBL/MBL/AmpC/MRSA producers. 
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PSEUDOMONAS IN NA 
 
 
 
 
 
 
 
 
 
 
BIOCHEMICAL REACTONS OF  PSEUDOMONA 
AERUGINOSA  
 
 
 
 
 
 
 
 
 
 
        PHENOTYPIC CONFIRMATORY FOR ESBL 
  
 
 
 
 
 
 
 
CAZ+CLAV=ceftazidime 30 µg+clavulanic acid 10 µg (
 
MIC REDUCTION TEST 
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CAZ=ceftazidime 30 µg 
≥5mm than CAZ)
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MIC to 512 µg of ceftazidime along with clavulanic acid 
 
 
MBL DETECTION  
 
Combined disc test Ceftazidime+EDTA  
CEFTAZIDIME – IMIPENAM ANTAGONISM TEST 
 
Flattening of the radius of the zone of inhibition produced  
on the side nearest to the imipenem disk 
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CEFTAZIDIME – IMIPENAM ANTAGONISM TEST 
 
Flattening of the radius of the zone of inhibition produced  
on the side nearest to the imipenem disk 
AMP –C DISK TEST 
 
 
 
 
 
 
Flattening or indentation of the cefoxitin inhibition zone in 
 the vicinity of the test disk 
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DETECTION OF MRSA USING CEFOXITIN DISC 
 
Cefoxtin Zone Size = ≤21mm - MRSA 
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CTX-M 
 
Lane One  : DNA Ladder 
Lane Two   : 120 bp 
Lane Three : 120 bp 
SHV 
  
 
 
  
Lane One  : DNA Ladder 
Lane Two   : Negative 
Lane Three : 276 bp 
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TEM 
 
 
 
 
 
 
Lane One  : DNA Ladder 
Lane Two   : 148 bp 
Lane Three : DNA Ladder 
Lane Four  : 148 bp 
Lane Five  : 148 bp 
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DISCUSSION 
This study aims at determining the common bacterial isolates, their 
antimicrobial susceptibility pattern, MRSA and ESBL and Amp C 
producers causing Chronic Suppurative Otitis Media. This study was 
conducted in all age groups among 212 patients who were diagnosed as 
CSOM. Both male and female patients were observed. The observations 
were recorded, analyzed and discussed as follows. 
  As per table 1 all age groups were included. Age of patients studied 
ranges from 0-80years, the oldest case was 76 years of age. Patients within 
the age of 21-30 years were 55(25.94%) and in the age group of 31-40 
years were 47(22.16%). which is similar to the observations in the study 
done by Shashidhar Viswanath et al
21
and Rejitha IM
72
 et al which showed 
21(22.34%) and 30% in the age group of 21-30 years. While studies done 
by Oguntibeju OO et al69 showed that CSOM was common below 30 years 
of age.
 
As per table 2 In our study, Males 110(51.88%) and Females 
102(48.11%) were suffering from CSOM which shows male 
preponderance. These findings are in accordance with the observations by 
Harvinder Kumar et al
3
 and Poorvey et al
4
 whereas Maji et al
5
 and Rajat  
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Prakash et al
6
 shows females are affected more than males. According to 
our study, males and females in the age group of 21-30 years suffered from 
Chronic Suppurative Otitis Media more significantly than other age groups. 
  As per table 3 Risk factors of CSOM such as illiteracy, low annual 
income and ear cleaning habits were assessed. 124(58.64%) patients had 
annual income of patients below 50000.103(48.59%) patients had studied 
10
th
std or below. 154(72.64%) patients had no habit of cleaning the ear 
regularly. This is in accordance with Md Mazharul Shaheen et al14. 
As per table 4 Discharge alone was seen in 115(52.83%). Deafness 
was associated with discharge in 51(24.06%). Earache was associated with 
discharge in 28(13.21%). All the three symptoms – discharge, deafness and 
earache was found in 21(9.09%). This is similar to the findings observed 
by Shashidhar Viswanath et al
21
 and Karan Sharma et al
8
. 
As per table 5 Direct smear positive and culture positive was seen in 
153(75%). In a study done by Shyamala R et al
73
 93% were found to be 
both smear as well as culture positive. 
As per table 6, 147(89.37%) were monomicrobial and 17(10.69%) 
showed polymicrobial pattern. This finding corroborates well with the  
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findings reported by Karan Sharma et al
8
, Poorvey et al
4
, Sanjay Kumar et 
al
20
 and Rajat Prakash et al
6
. 
  As per table 7 Number of culture positive ear swabs were 
157(74.06%) and 55(25.94%) were culture negative. This was coinciding 
with the studies done by Oguntibeju OO et al
69
.This was contrast to the 
study done by Sateesh Kumar Malkappa et al
74
 and Harvinder Kumar et 
al
3
. This could be due to prior antibiotic therapy and also due to microbial 
resistance to the antibiotics leading onto continuous purulent discharge 
from the ear.
 
As per table 8: In our study, Gram negative bacilli were predominant 
in 113(65.69%) cases of CSOM and Gram Positive cocci was found in 
57(34.30%) which is comparable with the study done by Harvinder Kumar 
et al
3
 which showed that 59.94% gram negative bacilli and 37.7% were 
Gram Positive cocci. Similarly, Sateesh Kumar Malkappa et al
74
 where 
gram negative bacilli were 69.84% and gram positive isolates were 31%. A 
contrast study with the predominance of gram positive cocci was by 
various investigators Poorvey et al
4
 and Rajat Prakash et al
6
. 
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As per table 9 in the present study, the predominant organism 
isolated was Pseudomonas aeruginosa 80(46.10%) followed by 
Staphylococcus aureus 46(26.59%), Klebsiella pneumoniae 25(14.45%), 
Coagulase negative Staphylococcus aureus 9(5.20%), Proteus mirabilis 
7(4.05%), Enterococcus faecalis 5(2.89%) and Escherichia coli 1(00.58%). 
This is in accordance to the fact reported by Harvinder Kumar et al
3
, 
Oguntibeju OO et al
69
, Shashidhar Viswanath et al
21
, Maji et al
5
, Poorvey et 
al
4
, Sateesh Kumar Malkappa et al
74
, and Sanjay Kumar et al
20
 that 
Pseudomonas aeruginosa was the most common organism in CSOM.  
Arti Agrawal et al
75
 found that Staphylococcus aureus was the 
predominant organism in their study, Rajat Prakash et al6 also observed 
that Staphylococcus aureus was the commonest organism causing CSOM 
followed by Pseudomonas aeruginosa whereas Saini et al
76
 reported that in 
Pediatric age group, Staphylococcus aureus was the commonest organism 
and in adult, Pseudomonas aeruginosa was the predominant organism in 
CSOM 
As per table 10in the present study among the Gram negative 
isolates, Pseudomonas aeruginosa showed 77(96.25%) sensitivity to 
amikacin and 77(95%) were sensitivity to ofloxacin. All Gram negative 
isolates were 100% sensitive to imipenem and Piperacillin –Tazobactam  
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except Pseudomonas aeruginosa which showed 78(97.50%) sensitivity to 
Piperacillin –Tazobactam.  
In the study done by Poorvey et al
4
 90-100% sensitivity was reported 
among Gram negative isolates to amikacin. In our study, among Klebsiella 
pneumoniae isolates, 25(100%) sensitivity was reported for imipenem and 
Piperacillin/Tazobactam. 20 (80%) and 18(72%) were sensitive to 
amikacin and ofloxacin respectively whereas it showed 14(56%) sensitivity 
to gentamicin.  15(60%) sensitivity was found to ceftazidime and 
cefotaxime. Among Proteus mirabilis,6 (85.71%) were sensitive to 
amikacin and ofloxacin. 
Amoxycillin showed less than 30% sensitivity to Klebsiella 
pneumoniae and Proteus mirabilis. 
As per table 11 of the 46 Staphylococcus aureus, 41(89.13%) was 
sensitive to amikacin, 40(86.95%) to ofloxacin and 20(43.44%) to 
cotrimaxozole. Erythromycin showed 31(67.39%) sensitivity. 
100%sensitivity was reported to vancomycin and linezolid. Enterococcus 
faecalis was 4(100%) sensitive to vancomycin and linezolid. 
 
 118 
 
 
 
In a study done by Rajat Prakash et al
6
 Staphylococcus aureus show 
95% sensitivity to amikacin and 82%sensitivity to ciprofloxacin. Harvinder 
Kumar et al
3
 also reported that Staphylococcus aureus show 90% 
sensitivity to amikacin and 68% sensitivity to erythromycin. Oguntibeju et 
al
69
 reported that Staphylococcus aureus shows 40% sensitivity to 
cotrimaxazole. 
As per table 12: ESBLs were screened by observing resistance to 
third generation cephalosporin - cefotaxime and ceftazidime in which out 
of 33 Gram negative bacilli 10(30.30%) were ESBL producers. The 
distribution of ESBL are as follows, out of 25 Klebsiella pneumoniae, 
10(40%) were found resistant to both ceftazidime and cefotaxime. Proteus 
mirabilis and Escherichia coli showed 100% sensitivity to both 
cephalosporins. 
As per table13: 10 Klebsiella pneumoniae  which were resistant to 
3
rd
 generation cephalosporin were further confirmed by phenotypic 
confirmatory test/disc potentiation test. This method showed 10 ESBL 
producers.This is in accordance with the study done by IM Rejitha et al
72
 
and NB Swarooprani et al
77
. 
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As per table 14 and 15: Minimum inhibitory concentration (MIC) of 
Ceftazidime with clavulanic acid for the ESBL producers was done by 
Agar dilution method for 10 isolates, MIC of the isolates ranged from 
8µg/ml to 512µg/ml. in the presence of ceftazidime with 4µg/ml clavulinic 
acid, MIC of ESBL isolates ranged from 0.5µg/ml to 64µg/ml showing ≥3 
doubling dilution reduction in MIC. These observations confirmed ESBL 
producers in the test isolates. 
As per table 16 All the Ceftazidime and imipenem resistant 
Pseudomonas aeruginosa isolates were screened as probable MBL 
producers. Thus out of 80 isolates, 6 isolates were resistant to Ceftazidime 
whereas all the Pseudomonas aeruginosa isolates were 100% sensitive to 
imipenem. 
As per table 17 By Ceftazidime – EDTA Test method, out of 6 
isolates 1 (16.66%) was found to be MBL producer. This is similar to study 
by Agarwal G et al
78
. 
As per table 18 Screening for Amp C production was done by 
observing resistance to cefoxitin in which of the 113 enterobacteriaceae, 
12 were resistant to cefoxitin, out of which  9(7.96%) were Amp C 
producers. Amp C production was done by Amp C disk test and  
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ceftazidime – imipenem test. 3(2.65%) were Klebsiella pneumoniae and 
6(5.30%) were Pseudomonas aeruginosa. This is similar to study done by 
Singhal et al
52
 which reported that AmpC producers were about 8% 
among Gram negative isolates. 
As per table 19: 10 ESBL producing enterobacteriaceae which were 
phenotypically confirmed as ESBL producers were subjected to genotypic 
test by Polymerase Chain Reaction (PCR).three genes such as SHV, TEM 
and CTX-M associated with ESBL production was studied using the 
relevant primers for the corresponding genes. TEM genes were detected in 
3(30%) and SHV were detected in 4(40%).CTX-M was detected in 
3(30%). 
As per table 20: out of 46 Staphylococcus aureus isolates,   
9(19.53%) were resistant to cefoxitin.  9 were MRSA which was detected 
by cefoxitin disc diffusion method. This was similar to Arti Agrawal et al
75
 
which showed 20% MRSA producers. Prakash M et al
79
 also reported that 
18% were MRSA. Anupkumar Shetty et al
80
 reported that 36% were 
MRSA producers and Swarooprani NB et al
77
 showed 41.1% MRSA 
producers. A contrasting study by IM Rejitha et al
72
 showed 83.3% MRSA. 
In the present study, all MRSA strains showed 100% sensitivity to 
vancomycin and linezolid. 
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As per table 21: The outcome was noted in 189 cases only and the 
remaining lost follow up. Out of 189 cases recovery was seen in 169 and 9 
was MRSA Positive, 7 were ESBL positive and the remaining 153 did not 
harbour any ESBL/MBL/AmpC/MRSA producers. 
20 of them were operated for CSOM, out of them 3 were ESBL 
positive and 1 was MBL positive 16 of them were non 
ESBL/MBL/AmpC/MRSA producers. 
In this period of emerging drug resistance amongst bacteria, episodic 
monitoring of the microbiological profile of CSOM along with clinical 
association is indispensable as precise antibiotics for empirical therapy 
depends on the local antibiotic policy, followed by alteration in treatment 
based on the culture and antimicrobial susceptibility results. Before 
managing with antibiotics (either systemic or local) culture of ear discharge 
should be done in all CSOM patients. 
 
 
 
 
 
 
 122 
 
 
 
SUMMARY 
Two hundred and twelve patients with CSOM between Jan 2013 to 
August 2014 formed the study group. Specimens obtained from study 
group were cultured and bacterial isolates were identified by standard 
microbiological techniques. All age groups were involved .The oldest 
being 76 years. Males and females in the age group of 21-30 years suffered 
from Chronic Suppurative Otitis Media significantly more than other age 
group. In our study, the percentage of males 110 (51.88%) and the 
percentage of females was 102 (48.11%). 
Monomicrobial infection was 141 (89.80%) and Polymicrobial 
infection was 16 (10.19%). Culture positive ear swabs were 157(74.06%) 
and culture negative ear swabs were 55 (25.94%). The current study 
showed that Gram negative bacilli were 60(34.68%), the predominant 
bacteria isolated in patients with CSOM. Among Gram negative bacilli, 
pseudomonas aeruginosa was  found to be the most common bacterial 
pathogen isolated in our study and Staphylococcus aureus was the most 
common Gram positive organism isolated followed by Klebsiella 
pneumoniae.  
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In the present study, antibiotic sensitivity of all Enterobacteriaceae 
showed 100% sensitivity to imipenem and Piperacillin/Tazobactam except 
Pseudomonas aeruginosa which showed 78(97.50%) sensitivity to 
Piperacillin /Tazobactam. 77(96.25%) Pseudomonas aeruginosa, 20 (80%) 
Klebsiella pneumoniae and 6 (85.71%) Proteus mirabilis were sensitive to 
amikacin respectively. 76(95%) Pseudomonas aeruginosa, 18(72%) 
Klebsiella pneumoniae, 6(85.71%) Proteus mirabilis showed sensitivity to 
ofloxacin respectively. Amoxycillin showed less than 30% sensitivity in all 
Gram negative isolates. 
Antibiotic sensitivity of Staphylococcus aureus showed 100% 
sensitivity to vancomycin and linezolid. Among 46 Staphylococcus aureus, 
41(89.13%) was sensitive to amikacin and 40(86.95%) to ofloxacin. 
Erythromycin showed 31(67.39%) sensitivity. Enterococcus faecalis was 
4(100%) sensitive to vancomycin and linezolid. 
ESBLs were screened by detecting resistance to third generation 
cephalosporin - cefotaxime and ceftazidime in which out of 33 Gram 
negative bacilli 10(30.30%) were ESBL producers. The distribution of 
ESBL are as follows, out of 25 Klebsiella pneumoniae, 10(40%) were 
found resistant to both ceftazidime and cefotaxime. Proteus mirabilis and 
Escherichia coli showed 100% sensitivity to both cephalosporins. 
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Phenotypic confirmatory test/disc potentiation test was done to 
confirm ESBL production. 10 Klebsiella pneumoniae which were resistant 
to 3
rd
 generation cephalosporin were further confirmed by this method 
which showed 10 ESBL producers. Minimum inhibitory concentration 
(MIC) of ceftazidime with clavulanic acid for the ESBL producers was 
done by agar dilution method for 10 isolates, MIC of the isolates ranged 
from 8µg/ml to 512µg/ml. in the presence of ceftazidime with 4µg/ml 
clavulinic acid, MIC of ESBL isolates ranged from 0.5µg/ml to 64µg/ml 
showing ≥3 doubling dilution reduction in MIC. These observations 
confirmed ESBL producers in the test isolates. 
10 ESBL producing enterobacteriaceae which were phenotypically 
confirmed as ESBL producers were subjected to genotypic test by 
Polymerase Chain Reaction (PCR).three genes such as TEM, SHV and 
CTX-M associated with ESBL production was studied using the relevant 
primers for the corresponding genes. TEM genes were detected in 3(30%) 
and SHV were detected in 4(40%).CTX-M was detected in 3(30%). 
All the Pseudomonas aeruginosa isolates resistant to ceftazidime and 
imipenem were screened as probable MBL producers. Thus out of 80 
isolates, 6 isolates were resistant to Ceftazidime whereas all the 
Pseudomonas aeruginosa isolates were 100% sensitive to imipenem. By  
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Ceftazidime – EDTA Test method, out of 6 isolates 1 (16.66%) was found 
to be MBL producer. Whereas by imipenem –EDTA method none of them 
were MBL producers. 
Screening for Amp C production was done by observing resistance 
to cefoxitin in which of the 113 enterobacteriaceae, 9(7.96%) were Amp C 
producers. Amp C production was done by AmpC disk test and ceftazidime 
– imipenem test. 3(2.65%) were Klebsiella pneumoniae and 6(5.30%) were 
Pseudomonas aeruginosa. 
Among 46 Staphylococcus aureus isolates,   9(19.53%) were 
resistant to cefoxitin.  9 were found to be MRSA by cefoxitin disc diffusion 
method.  In the present study, all MRSA strains showed 100% sensitivity 
to vancomycin and linezolid. 
The outcome was noted in 189 cases only and the remaining lost 
follow up. Out of 189 cases recovery was seen in 169 and 9 was MRSA 
Positive, 7 were ESBL positive and the remaining 153 did not harbour any 
ESBL/MRSA producers. 
20 of them were operated for CSOM, out of them 3 were ESBL 
positive and 1was MBL positive 16 of them were not ESBL/MRSA 
producers. 
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CONCLUSION 
• The present study showed that Gram negative bacilli 60(34.68%) 
were the predominant bacteria isolated in patients with CSOM. 
 
• Among Gram negative bacilli, Pseudomonas aeruginosa was  
found to be the most common bacterial pathogen isolated in our 
study and Staphylococcus aureus was the most common Gram 
positive organism isolated followed by Klebsiella pneumoniae.  
 
• Among the Enterobacteriaceae isolates, 10(30.30%) were found to 
be ESBL producers and all of them showed 100% sensitivity to 
imipenem. 
 
• Among Pseudomonas aeruginosa isolates, 1 (16.66%) was found to 
be MBL producer. By Ceftazidime – EDTA Test method. Whereas 
by imipenem –EDTA   method none of them were MBL producers. 
• Among the Enterobacteriaceae isolates, 9(7.96%) were Amp C 
producers. 
• Among the Staphylococcus aureus isolates, 9(19.53%) were 
reported to be MRSA producers and all MRSA producers were 
100% sensitive to vancomycin and linezolid. 
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Thus, it is imperative to detect Extended Spectrum Beta Lactamases 
(ESBL) and Methicillin Resistant Staphylococcus aureus (MRSA) 
routinely in laboratories by using the various methods mentioned in our 
study. In CSOM, spread of resistant strains can be prevented by following 
simple measures like hand washing, appropriate use of broad spectrum 
antibiotics and early approach to medical care. In cases of middle ear 
infection, administration of antibiotics should be prescribed cautiously to 
prevent the emergence of bacterial resistance in the hospital and 
community. 
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PROFORMA 
 
NAME: 
AGE /SEX:    
OP/I.P NUMBER: 
ADDRESS: 
OCCUPATION: 
H/O PRESENT ILLNESS:                                       H/O DM/HT/CAD 
       DURATION 
       SYMPTOMS 
       SIGNS 
RISK FACTORS: 
 
PAST HISTORY: 
 
TREATMENT HISTORY: 
 
DIRECT GRAM STAIN 
 
CULTURE 
NUTRIENT AGAR 
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MAC CONKEY AGAR 
 
BLOOD AGAR 
 
ANTIBIOTIC SUSCEPTIBILITY PATTERN 
 
 
ESBL 
Phenotypic Confirmatory Test 
 
MBL 
Combined Disc Potentiation Test 
 
AMP C 
AmpC Disk Test 
Ceftazidime –Imipenem Antagonism Test 
 
MRSA 
Cefoxitin Disc Diffusion Test 
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CONSENT FORM 
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APPENDIX 
 
GRAM STAIN 
Primary stain -crystal violet 10g 
Absolute alcohol 100ml Distilled water1litre 
Grams iodine-iodine 10g  
Potassium iodide 20g Distilled water-1litre 
Acetone 
Counter stain-dilute carbol fuchsin 
1. Flood the crystal violet for one minute 
2. Rinse gently with distilled water 
3. Flood the slide with grams iodine for one minute 
4. Rinse gently with distilled water 
5. Decolourise with acetone for only 2-3 secs. 
6. Rinse gently with distilled water to remove excess of decolouriser 
7. Flood the slide with dilute carbol fuchsin for one minute 
8. Rinse the slide with distilled water air dry and examine under oil 
immersion objective 
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PEPTONE WATER 
 
Peptone   10g 
Sodium chloride  5g 
Distilled water   1 litre 
 
Dissolve the ingredients in warm water, adjust the ph to 7.4 -7.5 and 
filter. Distribute as required and autoclave at 121 degree Celsius for 15 
mins. 
 
MacConkey agar:- 
This is a useful medium for the cultivation of enterobacteriaceae. It 
contains a bile salt to inhibit non-intestinal bacteria and lactose with 
neutral red to distinguish the lactose- fermenting coli forms from the 
lactose -non-fermenting Salmonella and Shigella groups. The 
concentration of sodium taurocholate may be reduced to suit less tolerant 
organisms. The omission of sodium chloride from the medium prevents the 
spreading of Proteus colonies. 
Peptone       20 g 
Sodium taurocholate, commercial   5 g 
Water        1 litre 
Agar        20 g 
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Neutral red solution, 2% in 50% ethanol   3.5 ml  
Lactose, 10% aqueous solution    100 ml  
 
Dissolve the peptone and taurocholate (bile salt) in the water by 
heating. Add the agar and dissolve it in the steamer or autoclave. If 
necessary, clear by filtration. Adjust the pH to 7.5. Add the lactose and the 
neutral red, which should be well shaken before use, and mix. Heat in the 
autoclave with 'free steam' (c. 100
o
 C) for 1hr., then at 115
o
 C for 15 min. 
Pour plates. 
 
NUTRIENT AGAR:-              Gm/L 
Peptic digest of animal tissue    5.00 
Beef extract       1.50 
Yeast extract                5.00 
Agar        15.00 
Dissolve the contents in water and mix by heating Autoclave at 121
o
 
C for 15 minutes. Adjust pH to 7.4 + 0.2. Pour 20-25 ml of 9 cm dia. Petri 
dishes to give 4 mm thickness.  
BLOOD AGAR: 
Sterile sheep blood     50 ml 
Peptone       10 g 
Beef extract       3g 
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Sodium chloride      5 g 
Distilled water      1000 ml 
 
Autoclave the nutrient agar base at 121
o
 C for 15 minutes and blood 
with sterile precautions and distribute in Petri dishes.  
 
MUELLER HINTON AGAR:- 
Beef infusion     300 ml 
Casein Hydrolysate   17 gm 
Starch      1.5 gm 
Agar      10 gm 
Distilled water    1000 ml  
 
Emulsify the starch in a small amount of cold water, pour into the beef 
infusion and add the casein-Hydrolysate and the agar. Make up the volume to 
1000 ml (1 litre) with distilled water. Dissolve the constituents by heating gently 
at 100
o
 C with agitation. 
 
Adjust the pH to 7.4. Dispense in screw-capped bottles and sterilize by 
autoclaving at 121 
o
 C for 20 minutes. 20 to 25 ml of it is poured into petridishes 
of 9 cm diameter to give a thickness of 4mm. 
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McFarland's Turbidity Standard for inoculum preparation 
 
A Barium sulphate 0.5 McFarland standards was prepared as follows  
1. A 0.5 ml of 0.048mol/L of Barium chloride was added to 99.5 ml of 0.18 
mol/L of H2SO4 with constant stirring to maintain a suspension. 
2. Correct density of the turbidity standard was verified by using a 
spectrophotometer. The absorbance of 625nm should be 0.08 to0.10 for 
the 0.5 McFarland standards. 
3. The Barium sulphate suspension was transferred in 4-6 ml to a screw 
capped tube of the same size as those used in growing or diluting the 
bacterial inoculam. 
4. These tubes were tightly sealed and stored in the dark at room 
temperature. 
5. The Barium sulphate turbidity standard was vigorously agitated before 
each use and inspected for a uniform turbid appearance 
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DIFFERENTIATING CHARACTERS OF ISOLATES COMMONLY 
AMONG GRAM NEGATIVE BACILLI OBSERVED IN EAR DISCHRGE 
 
Organism 
  
  
  
  
T
S
I 
C
it
ra
te
 
In
d
o
le
 
O
x
id
a
se
 
C
a
ta
la
se
 
G
lu
co
se
 
L
a
ct
o
se
 
S
u
cr
o
se
 
M
a
lt
o
se
 
M
a
n
n
o
se
 
M
o
ti
li
ty
 
Pseudomonas 
aeruginosa 
K/No 
change 
utilised - + + - - - + - + 
Klebsiella 
pneumoniae 
A/A with 
gas 
utilised - - + + + + + + - 
Proteus species A/A with 
H2S 
v + - + + - + - - + 
Escherichia coli A/A with 
gas 
Not 
utilised 
+ - + + + - + + + 
 
Note: A/A = Acid slant / Acid butt, + = Positive, - = Negative, v - Variable 
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DIFFERENTIATING CHARACTERS OF ISOLATES COMMONLY 
OBSERVED IN EAR DISCHARGE AMONG GRAM POSITIVE COCCI 
Gram 
strain 
catalas
e 
oxidas
e 
hemolysis 
coagulas
e 
Mannit
ol 
Bile 
esculin 
agar 
Bacitraci
n 
isolate 
Cocci  in  
cluster 
positiv
e 
negativ
e 
± positive Positive 
negativ
e 
resistant 
Staphylococcu
s  aureus 
Cocci  in  
cluster 
positiv
e 
negativ
e 
± negative 
Negativ
e 
negativ
e 
resistant 
Coagulase  
negative  
Staphylococcu
s aureus 
Cocci  in 
pairs 
positiv
e 
negativ
e 
± negative 
Negativ
e 
positive resistant Enterococci 
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ZONE SIZE INTERPRETATIVE CHART IN ACCORDING TO NCCLS 
Kirby-Bauer Chart 
Sl. 
No. 
Drug 
Disk 
Content 
µg  
Resistant 
mm or less 
Intermediate 
mm 
Sensitive 
mm or 
more 
1 Amoxycillin 10  14 mm 15-16 mm 17 mm 
2 Cotrimoxazole 1.25/23.75 10 11-15 16 
3 Cephalexin 30 14 15-17 18 
4 Ofloxacin 5 12 13-15 16 
5 Ciprofloxacin 5 15 16-20 21 
6 Gentamicin 10 12 13-14 15 
7 Cefotaxime 30 14 15-22 23 
8 Ceftazidime 30 14 15-17 18 
9 Linezolid 30 - - 21 
10 Amikacin 30 14 15-16 17 
11 Imipenem 10 13 15-16 16 
12 
Piperacillin/tazob
actum 
100/10 17 18-20 21 
13 Vancomycin 30 - - 15 
14 Nitrofurantoin 300 14 15-16 17 
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ABBREVIATION 
MHA    - Mueller Hinton Agar 
CSOM                    -        Chronic Suppurative Otitis Media. 
CLSI    - Clinical and Laboratory Standards Institute 
ESBL    - Extended Spectrum Beta Lactamase 
E- Test    - Epsilometer Test 
MBL   - Metallo Beta Lactamase  
TEM    - Temoniera 
SHV   - Sulphy Hydryl Variable 
MIC    - Minimum Inhibition Concentration 
EDTA   - Ethylene Diamine Tetra Acetic Acid. 
CLED   - Cysteine Lactose Electrolyte Deficient  
CFU   - Colony Forming Units. 
ATCC   - American Type Culture Collection 
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